

## CURRICULUM VITAE

### Georgia Sotiropoulou

Professor, Department of Pharmacy, School of Health Sciences  
University of Patras, University Campus, Rion-Patras 265 04, Greece  
Tel: +30 2610 962315 and 962316 Fax: +30 2610 997697  
Cellular: +30 6938031813 SKYPE: georgia.sotiropoulou4  
E-mail: [gdsotiro@upatras.gr](mailto:gdsotiro@upatras.gr) ORCID ID: 0000-0003-0747-4914  
<https://www.pharmacy.upatras.gr/index.php/el/staff/personell/professors/366-sotiropoulou-georgia>



AND Affiliated Investigator, Biomedical Research Foundation,  
Academy of Athens E-mail: [gdsotiro@bioacademy.gr](mailto:gdsotiro@bioacademy.gr)  
<http://www.bioacademy.gr/faculty-details/HMmM/gewrgia>  
2014, Visiting Professor, *Imagine* Institute INSERM UMR 1163,  
University Hospital Institute, Université René Descartes Paris 5-Sorbonne  
Paris Cité, Paris, France  
2016-2022 Visiting Professor, European University of Cyprus Cyprus

#### Public Profiles

Google Scholar: <https://scholar.google.gr/citations?user=Rlk1ntkAAAAJ&hl=en>  
Research Gate: [https://www.researchgate.net/profile/Georgia\\_Sotiropoulou](https://www.researchgate.net/profile/Georgia_Sotiropoulou)  
LinkedIn: <https://www.linkedin.com/pub/georgia-sotiropoulou/91/887/628>

#### Metrics

**Publications: > 110**

**h-index: 42**

**Patents: 5**

**Citations: > 6,085**

**GenBank™/PDB: 15**

**Mean citations per paper: > 55**

#### Education

1987: Ph.D. in Biochemistry, Aristotle University of Thessaloniki, Greece

1980: Diploma in Chemistry, University of Patras, Greece

#### Professional Appointments and Research Training

- 2019- Professor, Department of Pharmacy, School of Health Sciences University of Patras, GREECE
- 2015- Affiliated Investigator, Biomedical Research Foundation, Academy of Athens
- 2016- Visiting Professor, European University of Cyprus, Nicosia, CYPRUS
- 2014 Visiting Professor, *Imagine* Institute INSERM UMR 1163, University Hospital Institute,  
Jan-June Université René Descartes Paris 5-Sorbonne Paris Cité, Paris, FRANCE
- 2003-2019 Associate Professor, Department of Pharmacy, University of Patras, GREECE
- 1993-2003 Assistant Professor, Department of Pharmacy, University of Patras, Greece
- 1998 Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology/  
Dana-Farber Cancer Institute, Cancer Biology (c/o Prof Arthur Pardee), Boston, MA, USA
- 1993-1995 Harvard Medical School, Department of Genetics and Microbiology and Dana-Farber  
1996 (6 mo) Cancer Institute, Division of Cancer Genetics (c/o Prof Ruth Sager), Boston, MA, USA
- 1989-1993 Lecturer, Department of Pharmacy, University of Patras, Greece
- 1988-1989 Invited Researcher, Institute of Physical & Chemical Research RIKEN, Saitama, JAPAN
- 1987-1988 Postdoctoral Fellow, NCSR "Demokritos" and Laboratory of Enzymatic Technology,  
Technological University of Compiègne, Compiègne, FRANCE
- 1985 Graduate Fellow, Department of Biophysics, University of Osnabrück, GERMANY
- 1981-1985 Graduate Research Fellow, Institute of Biology, NCSR "Demokritos", GREECE

#### Hellenic Open University

- 2008-2015 Collaborating Faculty, Master's in Teaching Natural Sciences MSc
- 2005-2006 Collaborating Faculty, Studies in Natural Sciences

**Languages** Greek (mother tongue), English and German (fluent), French and Spanish (basic)

## Prizes-Awards

- 2018** (Athens, Greece) **Empirikion Research Prize**
- 2014** (NY, USA) **Parkinson's Disease Foundation's International Research Grant Award**
- 2013** (Toronto, Canada) **"The E. K. Frey - E. Werle Promotion Prize" (2013)**  
*Awarded by The E. K. Frey - E. Werle Foundation of the Henning L. Voigt Family (Munich, GER).*  
*For important contributions to contemporary research in the kallikrein-kinin system and related fields.*
- 1998** (Boston, USA) **Fulbright Senior Research Award**  
**Harvard Medical School and the Dana-Farber Cancer Institute**  
*"In vivo and in vitro assays for drug discovery-Functional evaluation of cystatin M as a tumor suppressor by the nude mouse assay. Development of an in vitro assay for screening anticancer drugs using the expression of the green fluorescent protein as a marker.*
- 1998** (Nyborg, Denmark) **American Association for Cancer Research (AACR) Award-AACR Meeting on "Proteases and Protease Inhibitors in Cancer".**  
*For the original identification and cloning of protease M (KLK6) gene and association to cancer.*
- 1996** (Florida, USA) **American Association for Cancer Research (AACR) Award-AACR Special Conference on "Proteases and Protease Inhibitors in Cancer Research".**  
*For the original identification and cloning of cystatin M gene and association to cancer.*
- 1993** (Boston, USA) **Fulbright Senior Research Award**  
**Harvard Medical School and the Dana-Farber Cancer Institute**  
*"Identification and characterization of molecular markers for cancer Isolation of anti-peptide antibodies based on the identified markers".*

### Ranking of Researchers and Scientists in Greece in 2017 (Google Scholar database):

298/7470 upper 3,9%

<https://www.scribd.com/document/354081237/Ranking-of-researchers-and-scientists-in-Greece-in-2017-according-to-Google-Scholar-database>

## Invited Reviewer for Research Grants

- Greece** Greek Secretariat of Research & Technology, Ministry of Education, State Scholarships Foundation
- Cyprus** Research Promotion Foundation
- UK** Breast Cancer Campaign, London  
Worldwide Cancer Research, Scotland
- Hungary** The Hungarian Scientific Research Fund, OTKA
- Poland** National Science Centre
- Austria** The Austrian Federal Ministry of Education, Science and Culture-The Austrian Genome Research Programme GEN-AU
- EU** Innovative Medicines Initiative, IMI; [www.imi.europa.eu](http://www.imi.europa.eu)-European Union and the European Federation of Pharmaceutical Industries; Call: "Molecular biomarkers - accelerating cancer therapy development and refining patient care"; invited
- Australia** Australian Government Department of Health Funding-Australian Prostate Cancer Research Centre.

## Current/Recent Funding

- HORIZON-KDT-JU-2022-2-RIA (HORIZON-KDT-JU-2022-2-RIA)  
Project Title: "Intelligent neural system for bidirectional connection with exoprostheses and exoskeletons",  
Acronym: NerveRepack, Project Duration: 2023-2027  
University of Patras (PI: Professor G. Sotiropoulou), Budget: 525.000 €/1.712.495 € (Greece); Total Budget: 15.575.733,70 €
- The Michael J. Fox Foundation for Parkinson's Research Award (MJFF), New York, USA - Fall 2022 RFP: *Accelerating Biological Understanding and Therapeutic Translation for Parkinson's Disease Program - Biology*  
Project Title: "Validation of KLK6 as a new therapeutic target for Parkinson's Disease",  
Grant ID: MJFF-022676, Budget: \$199,723.34, Project Duration: 2023-2025  
Partners: Department of Pharmacy, AUTH (Associate Professor Georgios Pampalakis); Department of Pharmacy, University of Patras (Professor Georgia Sotiropoulou); The Biomedical Research Foundation of the Academy of Athens (Researcher A' Kostas Vekrellis)
- Alzheimer's Association (Chicago, IL, USA)  
Project Title: "Targeting KLK6 for the treatment of Alzheimer's disease", Acronym: K6AD  
Grant ID: AARG-21-847642, Budget: \$120,000, Project Duration: 2021-2023  
Coordinator: Assistant Professor Georgios Pampalakis, Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki; PI for the University of Patras: Professor Georgia Sotiropoulou, Department of Pharmacy, University of Patras; PI for the Biomedical Research Foundation of the Academy of Athens: Researcher A' Kostas Vekrellis.
- ERA-NET/E-Rare-3: Joint Translational Call (2015) for "European Research Projects on Rare Diseases".  
Project Title: "Tracing the untackled facets of Peeling Skin Disease-Targeting epidermal proteolysis for treatment" (Propeka15) ["Ιχνηλατώντας τις ανεξερεύνητες πλευρές της νόσου PSD- Στόχευση της επιδερμικής πρωτεόλυσης για θεραπεία"]  
2015-2018, PI: G Sotiropoulou, Total/Partner 1 Budget: €469,197 / €100,000  
Ranked 5<sup>th</sup>/234 (top 2%)
- Parkinson's Disease Foundation (PDF), International Research Grants Program (IRGP), NY, USA; Project Title: "Novel insights into the properties and fate of naturally secreted alpha-synuclein"  
PDF-IRG-1441; 2014-2016, PI: G Sotiropoulou, Budget: \$165,000  
Ranked among 10/210 (top 4.8%)
- 2013 Fondation Santé Grants  
Project Title: "Is KLK6 protease the eluded regulator of extracellular α-synuclein?"  
2013-2015, PI: G Sotiropoulou, Budget: €40,000
- Europa Nostra 2014; Greece-France Bilateral Cooperation Project 2013-2015.  
Project Title: "Integration of novel mouse models to advance understanding of epidermal proteolysis in rare genetic skin diseases such as the Netherton Syndrome-Basic and translational aspects".  
2013-2015, ERADISK5, PI: G Sotiropoulou, Budget: €30,000
- Excellence Postdoctoral Grants (LS4-2139, Skink5)  
Project Title: "Delineation of KLK5-mediated proteolytic pathways in skin desquamation"  
2011-2014, PI: G Sotiropoulou, Budget: €150,000
- ΔΡΑΣΗ «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ» (ΕΥΔΕ ΕΤΑΚ-ΕΥΔ ΕΠΑνεΚ ΕΣΠΑ 2014-2020)  
QFytoTera - T1EΔK-00996  
2018-2021, PI for UPATRAS: G Sotiropoulou, Budget: €100.610  
Project Title: "Nanoemulsions of plant oils with moisturizing and insect repellent properties"  
Τίτλος στα Ελληνικά: "Νανογαλακτώματα φυτικών ελαίων με ενυδατικές και εντομοαπωθητικές ιδιότητες"

- ΔΡΑΣΗ «ΕΡΕΥΝΩ-ΔΗΜΙΟΥΡΓΩ-ΚΑΙΝΟΤΟΜΩ» (ΕΥΔΕ ΕΤΑΚ-ΕΥΔ ΕΠΑνΕΚ ΕΣΠΑ 2014-2020)  
BIOLUMIPD - Τ1ΕΔΚ-03884  
2018-2021, PI for UPATRAS: G Sotiropoulou, Budget: €170.000  
Project Title: "Development of improved biomarker technologies for the discriminative diagnosis of Parkinson disease"  
Τίτλος στα Ελληνικά: "Ανάπτυξη προηγμένης τεχνολογίας βιοδεικτών για την διαφοροδιάγνωση της νόσου Parkinson"
- Ερευνητικά Έργα ΕΛΙΔΕΚ για την Ενίσχυση Μεταδιδασκτόρων Ερευνητών/τριών-Θεματική περιοχή: Life Sciences (Medical and Health Sciences), Natural Sciences  
K6PD-1876 (Code: 1876)  
2018-2021, PI: G Pampalakis, Host Lab: UPatraPharmacy/G Sotiropoulou, Budget: €180,000  
Project Title: "α-synuclein prion-like particles: in vivo turnover and infectivity"

### Earlier Funding

- Farmaserve-Lilly  
2011, PI: G Sotiropoulou
- Karatheodoris, University of Patras Research Committee  
Project Title: "Evaluation of the role of KLK6 in breast cancer development and/or metastasis in a mouse model and investigation of underlying molecular mechanisms using biotechnology approaches"  
2007-2010, PI: G Sotiropoulou
- PENED2003 (03ΕΔ430), Greek Secretariat of Research and Technology  
Project Title: "Study of KLK6 function and mechanisms of transcriptional regulation in tumors. Analysis of DNA methylation for the development of molecular diagnostics for cancer. Identification of specific substrates, synthesis and validation of specific and selective inhibitors"  
2006-2008, PI: G Sotiropoulou
- PENED2003 (01ΕΔ557), Greek Secretariat of Research and Technology  
Project Title: "Development and validation of novel diagnostics for cancer molecular diagnosis and staging"  
2003-2005, PI: G Sotiropoulou
- PENED2003 (01ΕΔ557), Greek Secretariat of Research and Technology  
Project Title: "Immunomodulation of HER-2 (c-erbB2) oncogene by administration of IFN-γ to improve immunochemotherapy of patients with metastatic breast cancer with Trastuzumab"  
2003-2005, G Sotiropoulou: Collaborating Group Leader
- Research Grant provided by the Mount Sinai Hospital, Toronto, Ontario, CANADA  
Project Title: "Production and biochemical characterisation of recombinant human kallikrein 9 (hK9), human kallikrein 11 (hK11) and human kallikrein 12 (hK12)"  
2002-2003, PI: G Sotiropoulou
- PENED1999, Greek Secretariat of Research and Technology  
2000-2001, G Sotiropoulou: Collaborating Group Leader  
Project Title: "Pathophysiology of bone metastases from hormone-dependent cancers (prostate-breast): Urokinase, protease M and inhibitors of their enzymatic activities"
- NATO Collaborative Research Grant  
Project Title: "Characterization of selected proteases from human normal and tumor cells"  
1998-2001, PI: G Sotiropoulou
- K Karatheodoris, University of Patras Research Committee  
Project Title: "Cloning and analysis of cystatin M promoter and mechanisms of regulation and its inactivation in human breast cancers"



1998-2001, PI: G Sotiropoulou

- European Association for Cancer Research (EACR)  
2008 Mike Price Fellowship, sponsored by EACR and ECCO–European CanCer Organization  
Project Title: "Molecularly targeted aptamer-based therapeutics and diagnostics directed against specific tumor markers for epithelial cancers"  
Funded the sabbatical visit (for one year) of Assist Prof S Missailidis (Open University UK) in the Department of Pharmacy (c/o G Sotiropoulou)

### **Professional Affiliations**

American Association for Cancer Research (AACR) (1994), Women in Cancer Research (sponsored by the AACR) (1994), International Proteolysis Society (2006), The Kallikrein Society (2005), International Society of Enzymology (ISE) (2010), Association of Fulbright Scholars (1994), Hellenic Society of Biochemistry and Molecular Biology (1984), Association of Hellenic Chemists (1980)

**Invited Lectures:** > 110

**International Meeting Presentations (1994-):** >120

### **Organization of International/National Meetings, Conferences and Workshops: 16**

#### **Chair, 5<sup>th</sup> General Meeting of the International Proteolysis Society (IPS2007)**

Conference and Cultural Center, University of Patras, 20-24 October 2007

>530 international participants

#### **Chair:**

#### **International Satellite Postgraduate Course on «Proteomics: Methodologies and Applications»**

19-20 October 2007, Department of Pharmacy, University of Patras

#### **International Satellite Postgraduate Course on «Bioinformatics-Computational Methods in Biological Data Mining»**

19-20 October 2007, Department of Pharmacy, University of Patras

#### **International Satellite Postgraduate Course on «Enzyme Mechanisms and Kinetics»**

19-20 October 2007, Department of Pharmacy, University of Patras

#### **International Scientific Committee Member:**

**The 22<sup>nd</sup> Congress of the International and European Federations of Clinical Chemistry and Laboratory Medicine of Clinical Chemistry and Laboratory Medicine, IFCC-EFLM EuroMedLab2017; [www.athens2017.org](http://www.athens2017.org)**

Megaro Mousikis, Athens, Greece, June 11-15, 2017

#### **The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)**

Université F. Rabelais, Tours, France, 26-29 September 2017

#### **8<sup>th</sup> IEEE International Conference on Bioinformatics and BioEngineering (BIBE 2008)**

Royal Olympic Hotel, Athens, Greece, October 8-10, 2008

#### **1<sup>st</sup> International Symposium on Kallikreins (ISK2005)**

International Olympic Committee Congress, Lausanne, Switzerland, 1-3 Sept 2005

### **Organizing Committee Member:**

**Advances in Circulating Tumor Cells (ACTC2012): From Basic Research to Clinical Practice,**  
Astir Palace Vouliagmeni – Westin Resort, 26-29 September 2012

**4<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011):  
Biochemistry, Molecular Biology and Association to Disease**  
Rhodos Palace Hotel, Rhodes Island, Greece, 2-4 September 2011

**7<sup>th</sup> International Symposium on Minimal Residual Cancer (7<sup>th</sup> ISMRC Athens 09)**  
Astir Palace Vouliagmeni, Athens, Greece, September 16-19, 2009

**2<sup>nd</sup> International Symposium on Kallikreins (ISK2007)**  
Petros M. Nomikos Conference Center, Santorini Island, Greece, 16-18 October 2007

### **National Meetings, Conferences and Workshops – Member of Organizing Committee**

- **Workshop of the Hellenic Proteomics Society**  
Conference and Cultural Center of the University of Patras, 23 May 2006
- **2<sup>nd</sup> Biosciences Conference**  
Conference and Cultural Center of the University of Patras, 23-24 April 2007
- **57<sup>th</sup> Annual Meeting of the Hellenic Society of Biochemistry and Molecular Biology**  
Conference and Cultural Center of the University of Patras, December 2006
- **1<sup>st</sup> Biosciences Conference**  
Conference and Cultural Center of the University of Patras, 19-21 Μαΐου 2005

### **Invited Reviewer for scientific journals ( > 60 ):**

Analytica Chimica Acta | Anti-Cancer Agents in Medicinal Chemistry | BBA - Molecular Cell Research | BBA - Proteins and Proteomics | Biochimie | Bioengineered | BioEssays | Biological Chemistry | Biomaterials | Bioorganic and Medicinal Chemistry Letters | BJU International | BMC Cancer | BMC Genomics | British Journal of Dermatology | Cancer | Cancers | Cancer Biomarkers | Cancer Cell International | Cancer Investigation | Cellular & Molecular Biology Letters | Cell Proliferation | Clinical Biochemistry | Clinical Chemistry | Clinical Chemistry and Laboratory Medicine | Clinical Proteomics | Comparative Biochemistry and Physiology | Critical Reviews in Clinical Laboratory Sciences | Critical Reviews in Clinical Laboratory Sciences | Current Drug Discovery Technologies | Experimental Dermatology | Expert Review of Molecular Diagnostics | Expert Review of Proteomics | Frontiers in Oncology | Gene | Hypertension Research | International Journal of Biological Sciences | International Journal of Cancer | International Journal of Environmental Research and Public Health | Journal of Pharmacology & Clinical Toxicology | International Journal of Molecular Sciences | Journal of Investigative Dermatology | JID Innovations | International Journal of Peptide Research and Therapeutics | Journal of Pharmacology and Clinical Toxicology | Mammalian Genome | Molecular Biology and Evolution | Matrix Biology Plus | Molecular Biology Reports | Molecular Oncology | Molecular Therapy - Methods & Clinical Development | Natural Product Communications | Nature Structural and Molecular Biology | Novel Biomarkers | Oncogene | Oncotarget | PLoS ONE (editorial board) | Proteins and Peptide Letters (editorial board) | Scientific Reports | The Journal of Pathology | Thrombosis and Haemostasis | Tumor Biology

## **Administrative Activities**

Member of Faculty meeting (Department of Pharmacy, 1989-2018), Member of Faculty Reviewing Committees (1991-2018), Coordinator of Graduate Program in "Pharmaceutical Biotechnology and Biomedical Sciences" (Dept of Pharmacy; 2004-2010), Member of Senate (Syglitos) of the University of Patras (2002-2003), Member of Council of the International Proteolysis Society (IPS, 2005-2007), Member of Council of the International Society of Kallikreins (2004-2015), Member of PhD and MSc theses committees (1990-2015), Alternate member of the Research Committee of the University of Patras (2004), Alternate member of the national committee for narcotics (pharmacology), Academic consultant of DOATAP for Pharmacy and Pharmaceutical Sciences, Committee Member of the Center for Instrumental Analysis, University of Patras (1998-2004), Member of Committee for Graduate and Undergraduate Curriculum, Member of Committee for Academic Development, Member of Committee for Admission Exams in Biochemistry (Department of Pharmacy).

## **RESEARCH GROUP (2022)**

### **Postdoctoral Researchers**

Elini ZINGKOU

Diana PORTAN

Evangelos BISYRIS

### **Diploma Theses: > 50**

MSc and PhD Committee Member

UPatras, EKPA: > 30

### ***Supervisor:***

### **PhD Theses**

Evangelos BISYRIS (2021)

Nicolas KHOURY (2021)

Vasia-Samantha SYKIOTI (2020)

Eleni ZINGKOU (2018)

Maria KAPASA (2011)

Athanasia PAVLOPOULOU (2011)

Konstantinos DROSOPOULOS (2005)

Georgios PAMPALAKIS (2005)

Eleni DIONYSSOPOULOU (2001)

Eugenia DRAKOPOULOU (1993)

### **MSc Theses**

Helen CHARLA (2022)

Helen TSIAOUSHI (2021)

Christina GIANNAKOPOULOU (2020)

Kyriaki EVAGELATOU (2020)

Evangelia PROSNIKI (2012)

Andreas KRITIKOS (2014)

Georgios PAMPALAKIS (2002)

Theodoros TSETSENIS (2001)

## **University Teaching**

Department of Pharmacy, University of Patras

### **Undergraduate Courses:**

Pharmaceutical Biotechnology (and Laboratory Training) (2002-2021)

Cell Biology (2004-2021)

Molecular Biology-Genetics (and Laboratory Training) (2005-2010)

Introduction to Biotechnology (1996-2001)

Pharmacognosy I and II (1990-2003)

Diploma Thesis I and II (1996-2018)

### **Graduate Courses:**

Preclinical and Clinical Drug Evaluation (2018-2021)

Molecular Targets of Drug Action (2018-2021)

Applied Biotechnology and Bioinformatics (2018-2021)

Precision Therapeutics (2018-2021)

Pharmaceutical Biotechnology (2002-2018)

Specific Topics in Clinical Chemistry (2011-2013)

Biochemical Basis of Drug Action (1995-2012)

Advanced Biotechnology (2002-2011)

Molecular Diagnostics (2002-2011)

Molecular Biology of Cancer (2002-2011)

Molecular Biology and Biotechnology Techniques (2002-2011)

Bioinformatics and Introduction to Biomedical Research (2002-2011)

Biotechnology Principles (1995-2002)

Pharmaceutical Microbiology (1995-2002)

Natural Products-Pharmacognosy (1995-2002)

Computer Applications in Pharmaceutical Sciences (1995-2002)

### **Hellenic Open University (<http://www.eap.gr>)**

2008-2015 Collaborating Scientific Stuff (SEP), Master's in Teaching Natural Sciences MSc,  
Tutor for postgraduate course: "Organization of Matter in Life Systems"  
Module code: KFE53

2005-2006 Collaborating Scientific Stuff (SEP), Studies in Natural Sciences,  
Tutor for undergraduate course: "Cell structure and function". Module code: FYE31

## Current/Recent Collaborations

1. **Alain Hovnanian**, MD, PhD, Professor and Head  
*INSERM UMR S1164 IHU Imagine-Institut des maladies génétiques-Université Paris Descartes, Paris, FRANCE* URL: <http://www.genegraft.eu/main-investigators>
2. **Eleftherios P. Diamandis** MD, PhD, FRCP(C), FRSC, Professor  
*Hold'em for Life Chair in Prostate Cancer Biomarkers, Head of Clinical Biochemistry, Mount Sinai Hospital and University Health Network Professor and Head, Division of Clinical Biochemistry, Dept. of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CANADA* URL: <http://sites.utoronto.ca/acdclab>
3. **Kostas Vekrellis**, Researcher B'  
*Division of Basic Neurosciences, Biomedical Research Foundation, Academy of Athens, Athens, GREECE* URL: <http://www.bioacademy.gr/faculty-details/HMw/kostas>  
AND Visiting Professor (2011-present)  
*University of Oxford, Medical School, Department of Experimental Medicine, Radcliffe Department of Medicine, Oxford, UK*
4. **Oliver Schilling**, PhD, Group Leader, ERC Awardee  
*Emmy-Noether Research Fellow, Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, GERMANY* URL: [http://www.sgbm.unifreiburg.de/index.php?option=com\\_zooprofiles&task=userProfile&user=6585](http://www.sgbm.unifreiburg.de/index.php?option=com_zooprofiles&task=userProfile&user=6585)
5. **Guy Serre**, MD, PhD, Professor, Directeur  
*Unité Différenciation Epidermique et Autoimmunité Rhumatoïde (UMR 5165), UDEAR - UMR 5165 CNRS, 1056 INSERM, Université de Toulouse, Hôpital PURPAN, Place du Dr Baylac TSA 40031, Toulouse, FRANCE* URL: <http://www.udear.cnrs.fr/>  
**Nathalie Jonca**, Professor  
*CNRS UMR 5165 - INSERM U1056 - Toulouse III University, CHU Purpan, Place du Dr Baylac - TSA 40031, Toulouse, FRANCE* URL: <http://www.e2brn.eu/members/jonca.html>
6. **Andras Nagy**, Professor and Head and **Dr. Iacovos Michael**  
*Department of Molecular Genetics, University of Toronto and Mount Sinai Hospital and Samuel Lunenfeld Research Institute, Toronto, Ontario, CANADA*  
URLs: <http://www.mshri.on.ca/nagy/>  
<http://www.phenogenomics.ca/transgenics/links.html> and <http://www.lunenfeld.ca/researchers/nagy>
7. **George M Yousef**, MD, PhD, FRCPC (Path), MSc, MBBCh, Professor  
*Department of Laboratory Medicine, St. Michael's Hospital and Department of Laboratory Medicine and Pathobiology, University of Toronto, CANADA* URL: <http://www.stmichaelshospital.com/research/profile.php?id=yousef>
8. **Dimitra Kiritsi**, Assistant Professor, MD, FEBDV  
*Universitaetsklinikum, Klinik für Dermatologie und Venerologie University of Freiburg, Freiburg, Germany* URL: <https://www.uniklinik-freiburg.de/hautklinik/>
9. **Evi S. Lianidou**, Professor  
*Laboratory of Analytical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Department of Chemistry, University of Athens, Greece* URL: <http://en.actc-lab.chem.uoa.gr/>
10. **Vassileios Zoumpourlis**, Researcher A'  
*Biomedical Applications Unit, Institute of Biological Research and Biotechnology. National Hellenic Research Foundation, Athens, Greece* URL: <http://www.eie.gr/nhrf/institutes/ibrb/serviceunits/bau-en.html>

### **Earlier Collaborations:**

**Ruth Sager**, Head at DFCI, Professor, Member of the National Academy of Sciences USA, and the Academy of Sciences and Arts USA

*Division of Cancer Genetics, Dana-Farber Cancer Institute (DFCI), Department of Genetics and Microbiology, Harvard Medical School, Boston, MA, USA*

**Arthur B. Pardee**, Head at DFCI, Professor, Member of the National Academy of Sciences USA, and the National Academy of Sciences and Arts USA

*Division of Cancer Biology, Dana-Farber Cancer Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA*

**Bonnie F. Sloane**, Professor and Chair

*Department of Pharmacology, Wayne State Medical School, Detroit, MI, USA*

**Fransesc X. Aviles**, Professor and Chair

*Institut de Biologia Fonamental and Departament de Bioquímica Universitat Autònoma de Barcelona, Bellaterra (Barcelona), SPAIN*

**R. Manjunatha Kini**, Professor and Chair

*Department of Biological Sciences, Faculty of Science, National University of Singapore, SINGAPORE*

**Antonia Vlahou**, Staff Research Scientist - Professor Level

*Proteomics Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, GREECE*

**Aristotelis Chatziioannou**, Researcher B'

*Metabolic Engineering–Bioinformatics Programme, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, GREECE*

**Vassilis Georgoulas** and **Dimitris Mavroudis**, Professors and Head

*Laboratory of Tumor Cell Biology, Medical School, University of Crete, GREECE*



## Invited Lectures (2004-, Selection)

"KLK6 protease is implicated in the regulation of extracellular  $\alpha$ -synuclein and may repress its prion-like propagation"

Fondation Santé 2017 Fellows Symposium

Ionic Center, Plaka, Athens, Greece, October 6, 2017

Plenary Speaker: "Role of KLKs in the regulation of immune function"

The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017),

Université F. Rabelais, Tours, France, 26-29 September 2017

"KLK6 proteolysis is implicated in the regulation of extracellular alpha-synuclein species and may represent a novel therapeutic approach"

The International Society for Enzymology Annual Conference: Advances in Laboratory Medicine and Pathobiology 2017 (ISE2017), Santorini Palace, Fira, Thira (Santorini), Greece, June 16-19, 2017

"Rare skin syndromes provide insights and druggable targets for epidermal overdesquamation and inflammation"

"Advances in Laboratory Medicine and Pathobiology 2016" *Under the auspices of the International Society for Enzymology.*

Syros Island, Greece, July 1-4, 2016

"Novel transgenic models reveal druggable targets for skin inflammation"

National and Kapodistrian University of Athens, Chemistry Department, March 3<sup>rd</sup>, 2016

"Novel animal models for validation of KLK5 protease as a drug target for overdesquamating/inflammatory skin diseases".

1<sup>st</sup> International CRS Congress, Aegli Zappiou, Athens, Greece, May 27-28, 2015

"Insights into the roles of KLK5 protease in epidermal proteolysis, inflammation and cancer"

UDEAR - UMR 5165 CNRS - U1056, Université Toulouse III, Hôpital Purpan, Toulouse, France, May 6, 2015

"Unravelling the functions of KLK proteases in epidermal inflammation and in Parkinson's disease. Insights from new animal models"

Pierre et Marie Curie-Sorbonne Universités (UPMC), Paris, France, June 10<sup>th</sup>, 2014

"Emerging roles of KLK proteases. Insights from new animal models"

Imagine Institute, INSERM UMR 1163, Paris, France, June 25<sup>th</sup>, 2014

Plenary Speaker: "Insights into KLK functions from novel animal models"

5<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013) Biochemistry, Molecular Biology, and Association to Disease

St. Michael's Hospital, Toronto, Ontario, Canada, Sept 28-Oct 1, 2013

"Refining the roles of KLK proteases"

Université Paris 5 René Descartes, Hôpital Necker enfants malades, Paris, France 4<sup>th</sup> February 2013

"KLK proteases: A road under construction"

Research Seminars Series "Conférence Sézary"

Hôpital St Louis, Paris, France, February 7<sup>th</sup>, 2013

"Insights into unexpected functions of KLK5/6 proteases"

University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada, April 5<sup>th</sup>, 2012

"The miRNAs in cancer"

19<sup>th</sup> Postgraduate Conference in Clinical Oncology,  
Candia, Heraklion, Crete, Greece, 27-29 October, 2011

"Role of enzymes in human diseases: Human tissue kallikreins: Physiology and clinical applications",  
New Roles for Old Molecules: Enzymes in Personalized Medicine, International Society for Enzymology  
Pilot Beach Resort, Chania, Crete, Greece, 2-4 May 2010

"Emerging roles of human kallikrein-related peptidase 6 in cancer"

6<sup>th</sup> General Meeting of the International Proteolysis Society (IPS2009)-Workshop on "Kallikreins  
and other emerging serine proteases in disease"  
Surfers Paradise, Gold Coast, QLD, Australia, 26-31 October 2009

"A tumor protective role for KLK6 protease in breast cancer mediated by inhibition of epithelial-to-  
mesenchymal transition"

7<sup>th</sup> International Symposium on Minimal Residual Cancer  
Astir Palace Vouliagmeni, Greece, 16-19 September 2009

"Emerging roles of human kallikrein-related peptidase 6 in cancer"

6<sup>th</sup> General Meeting of the International Proteolysis Society  
Workshop on "Kallikreins and other emerging serine proteases in disease"  
Surfers Paradise QLD, Australia, October 26-31, 2009.

"KLK proteolytic cascade pathways in normal physiology and cancer"

3<sup>rd</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases;  
TUM, Munich, Germany, August 30–September 2, 2009

"A tumour protective role for human kallikrein 6 in breast cancer mediated by inhibition of epithelial-to-  
mesenchymal transition"

EMBO Workshop on "Can epigenetics influence reprogramming and metastatic progression?"  
6-9 October 2008, Banz Monastery, Bad Staffelstein, Germany

"Emerging roles of kallikreins in cancer"

"New Molecules in Cancer Therapeutics"  
Divany Caravel, Athens, Greece, 12-14 Οκτωβρίου 2007

"The emerging roles of human tissue kallikreins in cancer"

DYAX, Boston, Ma, USA, March 2006

"The emerging roles of human tissue kallikreins in cancer"

National Hellenic Research Foundation, Institute of Biological Research & Biotechnology  
*SEMINARS* 2006, 31 January 2006, Athens, Greece

"Human Kallikrein 6: Mechanisms of Epigenetic Silencing in Breast Tumors - A Role in Breast Cancer?"

Workshop on "Functional Genomics of Proteases"  
University of Bern, Bern, Switzerland, 20-22 November 2005

"Regulation of Human Kallikrein 6"

1<sup>ST</sup> International Symposium on Kallikreins  
International Olympic Committee Congress Center,  
Lausanne, Switzerland, August 31-September 3, 2005

"Αναδυόμενοι ρόλοι των ανθρώπινων καλλικρεϊνών στη μοριακή διάγνωση καρκίνου"

Επιστημονικό Συνέδριο Κέντρου Μοριακής Βιολογίας Νοσοκομείου ΥΓΕΙΑ, 17 Δεκεμβρίου, 2004

“Ταυτοποίηση και μελέτη γονιδίων για την κατανόηση και μοριακή διάγνωση καρκίνου”  
1ο Συνέδριο ΒιοΕπιστημών Πανεπιστημίου Πατρών, Πάτρα, 19-20 Μαΐου, 2005

## **ΆΛΛΕΣ ΔΙΑΛΕΞΕΙΣ**

6ο Πανελλήνιο Συνέδριο Φοιτητών Φαρμακευτικής, Αθήνα, Μάιος 2005  
Μεταπτυχιακό Πρόγραμμα Σπουδών Τμήματος Φαρμακευτικής Πανεπιστημίου Πατρών

5ο Πανελλήνιο Συνέδριο Φοιτητών Φαρμακευτικής, Πάτρα, 7-9 Μαΐου 2004  
“Φαρμακογονιδιωματική”

## **Referees**

1. **Eleftherios P. Diamandis, MD, PhD, FRCP, Professor**  
**Member of the Royal Academy of Sciences of Canada**  
**Associated Member of the Academy of Athens (Αντεπιστέλλον Μέλος Ακαδημίας Αθηνών)**  
Professor and Head, University of Toronto Medical School  
Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology  
Head of Clinical Biochemistry, Mount Sinai Hospital,  
University Health Network and Toronto Medical Laboratories  
Department of Pathology & Laboratory Medicine, Mount Sinai Hospital,  
Room m6-201, 60 Murray St., Toronto, Ontario, M5T 3L9 CANADA  
Tel: 416-586-8443 Fax: 416-586-8628  
E-mail: [ediamandis@mtsinai.on.ca](mailto:ediamandis@mtsinai.on.ca)  
URL: <http://www.acdclab.org/>
  
2. **Morley D. Hollenberg, DPhil., MD, FRSC, Professor and ex Head**  
Department of Pharmacology and Therapeutics and Department of Medicine  
University of Calgary, Faculty of Medicine  
3330 Hospital Drive NW, Calgary AB, T2N 4N1 CANADA  
Tel: +001-403-2206931 / 7204 Fax: +001-403-2700979  
E-mail: [mhollenb@ucalgary.ca](mailto:mhollenb@ucalgary.ca)

## ONGOING RESEARCH PROJECTS

- **SKIN DISEASES:** Unraveling the roles of KLK proteases in overdesquamating and inflammatory skin pathologies characterized by a defective epidermal barrier.  
Rare skin syndromes: Proof-of-principle for pharmacological targeting
- **PARKINSON DISEASE:** Investigating proteolytic pathways for pharmacological targeting
- **CANCER:** KLK proteases in cancer development and progression
- **VENOMICS:** Mining snake venoms for novel pharmaceutical proteins
- **THERANOSTICS:** Development and validation of activity based probes for serine proteases with dual applications as molecular diagnostics & candidate drug compounds (LMW protease inhibitors)

### Mouse Models

Transgenic / Knockout mouse models (for inflammation and cancer)

Cancer models (breast, skin)


**SKIN DISEASES: Unraveling the roles of KLK proteases in overdesquamating and inflammatory skin pathologies characterized by a defective epidermal barrier.**

**Rare skin syndromes: Proof-of-principle for pharmacological targeting**


Our group is interested in the identification and preclinical validation of new drug targets for the therapeutic manipulation of two rare skin diseases: the Netherton syndrome and the Peeling Skin Syndrome-Type B (PSD). Although their genetic basis is distinct, both these diseases are characterized by severe overdesquamation, extensive inflammation, and allergies. Moreover, in both diseases the KLK5 protease is highly activated in the epidermis of patients. Currently, no therapy exists for these devastating diseases, which can be fatal due to the severe skin barrier defect. Studying these rare syndromes will provide proof-of-principle for the design of specific targeted drugs for more common skin diseases, such as atopic dermatitis, rosacea, and psoriasis.

### Netherton Syndrome

NS is a severe type of ichthyosis, with prevalence 1:200,000 births, and it is caused by inactivating point mutations in the *SPINK5* gene encoding the LEKTI inhibitor of KLKs and other serine proteases. LEKTI deficiency results in hyperactivation of KLK proteases in the epidermis. These unopposed proteolytic activities lead to premature dissociation of the stratum corneum at the junction with the stratum granulosum. The phenotype is severe desquamation and inflammation that often leads to neonatal death due to dehydration. The syndrome is recapitulated in *Spink5*<sup>-/-</sup> mice that are born normal and die quickly within <5 h from birth. Using novel mouse models, such as *Klk5*<sup>-/-</sup> mice and *Spink5*<sup>-/-</sup>*Klk5*<sup>-/-</sup> double knockout mice, our group in collaboration with the group of Professor Alain Hovnanian (Imagine Institute, INSERM, Necker Hopital, Paris, France) demonstrated recently that KLK5 is a key molecule for pharmacological inhibition in order to reverse the cutaneous hallmarks of NS (PLoS Genetics Sept 2015). <http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1005389>




*Can targeting of KLK5 rescue the NS phenotype?*



**Proposed proteolytic cascade implicated in skin desquamation and inflammation.**

In normal skin, KLK serine proteases in the stratum corneum (SC) act to degrade the intercellular adhesion proteins DSG1, DSC1, and CDSN leading to corneocyte shedding (desquamation) and skin renewal. LEKTI encompasses 15 domains and the corresponding peptides (generated proteolytically) inhibit different serine protease activities in the epidermis. A finely tuned balance of proteases and LEKTI ensures physiological skin desquamation. In NS patients, genetic defects in *SPINK5* lead to the production of a truncated LEKTI precursor protein containing fewer/or no functional inhibitor domains resulting in highly elevated proteolytic activities in the SC, excessive degradation of desmosomal adhesion proteins leading to overdesquamation and a severe skin barrier defect associated with sustained/constitutive epidermal inflammation and atopy.



**Ablation of *Klk5* rescues skin and whisker anomalies and restores epidermal function in the Lekti-deficient background (*Spink5<sup>-/-</sup>*).** The severe skin barrier defect is reversed in *Spink5<sup>-/-</sup>Klk5<sup>-/-</sup>* mice as demonstrated by impermeability of the toluidine blue dye in sharp contrast to the deep blue stain of *Spink5<sup>-/-</sup>* mice. Photos were taken 30 hours after birth and 5 hours for *Spink5<sup>-/-</sup>*.

Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G\*, Hovnanian A.\* (2015) Elimination of KLK5 reverses the hallmarks of Netherton syndrome. PLoS Genet 11(9):e1005389


## Peeling Skin Disease or Peeling Skin Syndrome-Type B

PSD has a similar phenotype with NS but it is caused by mutations in the *CDSN* gene encoding for the corneodesmosin. *CDSN* is either required for the formation of mechanically resistant corneodesmosomes that hold together the corneocytes of the stratum corneum or its role is to protect desmosomes from premature proteolysis. It is a very rare disease with 30 cases reported worldwide.

Recently funded by the ERA-NET/E-Rare-3 program we will investigate whether targeted inhibition of the KLK5 protease is sufficient to fully or partially alleviate the symptoms of the disease and to examine the molecular pathways associated with PSD.



Mallet et al. (2013) *Br J Dermatol* 169: 1322-1325.



Leclerc et al. (2009) *J Cell Sci* 122: 2699-2709.

## Funding

### PSS type B

- ✓ ERA-NET/E-Rare-3: Joint Translational Call (2015) for "European Research Projects on Rare Diseases".

Project Title: "Tracing the untackled facets of Peeling Skin Disease-Targeting epidermal proteolysis for treatment" (Propekal5) [2015-2018]

Coordinator (PI): Georgia Sotiropoulou

Partners: Nathalie Jonca (University of Toulouse III and Hôpital Purpan, Toulouse, France) and Oliver Schilling (Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany).

### Netherton

- ✓ Europa Nostra2014; Greece-France Bilateral Cooperation Project 2013-2015.  
Project Title: "Integration of novel mouse models to advance understanding of epidermal proteolysis in rare genetic skin diseases such as the Netherton Syndrome-Basic and translational aspects" [ERADISK5, 2013-2015, PI: Georgia Sotiropoulou]
- ✓ Excellence Postdoctoral Grants (LS4-2139, Skink5)  
Project Title: "Delineation of KLK5-mediated proteolytic pathways in skin desquamation" [2011-2014, PI: Georgia Sotiropoulou]

### Patent


Hovnanian A, Sotiropoulou G, Pampalakis G, Furio L. (2014) "Methods and pharmaceutical compositions for the treatment of Netherton syndrome". Application Nr: EP14153629.2 Priority date: 2014-02-03; Filing date: 2015-02-02; Publication date: 2015-08-06, WO2015114144A1

<https://patents.google.com/patent/WO2015114144A1/en?q=klk5&q=inhibitors>



## PARKINSON DISEASE: Investigating proteolytic pathways for pharmacological targeting

A hallmark of Parkinson Disease (PD) is the presence in the brain of intracellular inclusions of  $\alpha$ -synuclein protein termed Lewy bodies or Lewy neuritis. Alpha-synuclein was thought to be an intracellular protein until recently when it was demonstrated that  $\alpha$ -synuclein is also a secreted protein and, importantly, can spread from cell-to-cell in a prion-like mechanism. Nonetheless, the mechanisms that regulate the turnover of extracellular  $\alpha$ -synuclein are unknown. In collaboration with Kostas Vekrellis' Group at the Biomedical Research Foundation of the Academy of Athens, we suggested that kallikrein-related peptidase 6 (KLK6) mediates the degradation of extracellular  $\alpha$ -synuclein directly and *via* a proteolytic cascade that involves metalloprotease(s). We also found that association of naturally secreted  $\alpha$ -synuclein with lipids renders it resistant to proteolysis (Ximerakis M et al. FASEB J 2014). These findings provided the first evidence that physiological modifications affect the biochemical behavior of secreted  $\alpha$ -synuclein and that a proteolytic activation cascade may be involved in its catabolism, thus, providing novel insights into mechanisms and potential targets for therapeutic intervention. It should be noted that KLK6 is a serine protease highly expressed in the nervous system, while in synucleinopathies, including Parkinson disease, the levels of KLK6 inversely correlate with  $\alpha$ -synuclein in CSF. By degradomic profiling we analyzed the repertoire of proteases activated by KLK6 in a neuronal environment and found that KLK6 activates the proMMP2 and ADAMTS19, which in turn can cleave the  $\alpha$ -synuclein. Importantly, we showed that recombinant and naturally secreted KLK6 can readily cleave  $\alpha$ -synuclein fibrils that have the ability for cell-to-cell propagation. Using our recently generated *Klk6* knockout mice and established transgenic models for PD, we study the roles of KLK6 in the turnover of extracellular  $\alpha$ -synuclein and  $\alpha$ -synuclein fibrils and their propagation *in vivo*. It appears that KLK6-deficient primary cortical neurons have increased ability for  $\alpha$ -synuclein fibril uptake. By use of new adenoviral vectors for KLK6 delivery we demonstrate that the levels of extracellular  $\alpha$ -synuclein can be regulated by neuronally secreted KLK6 (Pampalakis et al. Oncotarget 2016). Our findings open up the possibility to exploit KLK6 as a novel therapeutic target for Parkinson disease and other synucleinopathies.



**Schematic representation of the proposed proteolytic cascade leading to proteolysis of  $\alpha$ -synuclein monomers and fibrillar strains (Pampalakis et al. Oncotarget 2016)**

### Funding:


- ✓ Parkinson's Disease Foundation (PDF), International Research Grants Program (IRGP), NY, USA; Project Title: "Novel insights into the properties and fate of naturally secreted alpha-synuclein" [2014-2016]
- ✓ 2013 Fondation Santé Grants: "Is KLK6 protease the eluded regulator of extracellular  $\alpha$ -synuclein?" [2013-2015]



## CANCER: KLK proteases in cancer development and progression

### Selection of recent studies:

Sidiropoulos KG, Ding Q, Pampalakis G, White NMA, Boulos P, Sotiropoulou G\*, Yousef GM\* (2016) KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. *Mol Oncol* 10: 993-1007. <https://www.ncbi.nlm.nih.gov/pubmed/27093921>



### A proposed model for the prediction of KLK6-miRNA interactions

Sidiropoulos et al.  
*Molecular Oncology* 2016

Sidiropoulos KG, White NMA, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, Sotiropoulou G, Yousef GM. (2014) Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. *Oncoscience* 1: 709-724.

<https://www.ncbi.nlm.nih.gov/pubmed/25593998>


Pampalakis G, Politi AL, Papanastasiou A, Sotiropoulou G. (2015) Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer-A new pool of biomarkers. *Genes Cancer* 6: 472-479.

<https://www.ncbi.nlm.nih.gov/pubmed/26807200>

Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G. (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. *Oncotarget* 15: 2390-2403. <http://www.ncbi.nlm.nih.gov/pubmed/24158494>

Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. (2009) A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. *Cancer Res* 69: 3779-3787.

[http://www.pharmacy.upatras.gr/media/GSotLub/1\\_CancerRes2009withSupplData.pdf](http://www.pharmacy.upatras.gr/media/GSotLub/1_CancerRes2009withSupplData.pdf)




Pampalakis et al. *Oncotarget* 2014


## MOUSE MODELS

### Transgenic / Knockout Mouse Models (for Inflammation and Cancer)

Recently, we generated transgenic mice that carry a targeted deletion of either the *Klk5* or the *Klk6* protease, in collaboration with Dr. Iacovos Michael and Prof Andras Nagy (University of Toronto, Canada). The scheme below shows the targeting cassette used for the generation of *Klk5*<sup>-/-</sup> mice, which allows for a global or a conditional knockout.



In addition, we have generated a novel transgenic/knockout mouse (NGL *Klk5*<sup>-/-</sup>) to monitor Nf-κB activation *in vivo* in the whole animal (shown in the figure below). In transgenic *Ngl* mice a reporter luciferase gene is integrated. The Nf-κB reporter is under the control of a minimal promoter carrying eight Nf-κB consensus sequences upstream of the firefly luciferase gene. Skin inflammation is induced by TPA according to established protocols and Nf-κB activity is monitored with IVIS bioluminescence imaging under anesthesia.



### Cancer models

#### 1. Tumor xenografts in immunocompromised mice


Our group uses SCID mice to study cancer growth and dissemination. Cancer cells (either parental or genetically modified by specific gene transfer) are xenotransplanted orthotopically onto SCID mice and primary tumor formation is monitored for several weeks depending on tumor growth rates. At the end of the experiment, mice are euthanized and tumor progression to metastatic sites in vital organs (lung, liver, brain, bone) is recorded. Tumors and their normal adjacent tissues are resected for histological observation by E/H staining and immunohistochemistry. We employed such models to elucidate the role(s) of KLK5 and KLK6 in human breast cancer. A typical experiment is shown in the figure on next page.

#### Relevant References

Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. *Oncotarget* 15: 2390-2403. <http://www.ncbi.nlm.nih.gov/pubmed/24158494>


Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G (2009) A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. *Cancer Res* 69: 3779-3787.

[http://www.pharmacy.upatras.gr/media/GSotLub/1\\_CancerRes2009withSupplData.pdf](http://www.pharmacy.upatras.gr/media/GSotLub/1_CancerRes2009withSupplData.pdf)



## 2. Tumor Metastasis Assay - Tail Vein Assay

Metastatic breast cancer cell lines (e.g. MDA-MB-231, MDA-MB-468) are injected *via* the mice tail vein, as shown in the figure below. Eight weeks post-injection visible tumors are present in the lungs (and other vital organs) of the injected mice, which are excised, quantified, and biopsied to assess metastatic disease.




## 3. Chemical carcinogenesis in transgenic mice

We use knockout models to delineate the role of proteases in cancer development. To investigate the possible role(s) of KLK5 and KLK6 proteases in skin cancer we employ chemical carcinogenesis in *Klk5<sup>-/-</sup>* and in *Klk6<sup>-/-</sup>* mice. Skin tumors are induced by two different schemes: DMBA/TPA and DMBA/DMBA. Our goal is to find new KLK-mediated pathways that are associated with the different stages of tumorigenesis, *i.e.*, initiation, promotion, and metastatic progression. Since chemical carcinogenesis in mice is an inflammation-driven process it is expected to reveal the inflammatory mechanisms implicated in skin cancer. In this direction we also apply two well-established systems of chemical-induced inflammation, *i.e.*, the irritant and the allergic contact dermatitis, in order to further elucidate the role of KLKs in skin inflammation. Finally, we also employ the model of methylcholanthrene-induced fibrosarcomas to delineate the role of KLKs in this type of cancer.

## VENOMICS: Mining snake venoms for novel pharmaceutical proteins

Venomous snakes are "living Pharmacies" unexploited to the largest extent. They are regarded as "oceans of opportunity" for the identification of novel bioactive molecules. Relative to other organisms, snake venoms evolve at greatly accelerated rates, thus, they present remarkable variety. Widely prescribed drugs - as for example the captopril for the treatment of hypertension and some types of congestive heart failure - were discovered from knowledge of venom toxins. To identify novel toxins, we analyse the transcriptome of the venom gland by generating full-length cDNA libraries and sequencing of clones. By integrated HTP proteomics (venomics) and bioinformatics approaches we analyse the complete venom proteome ("venome", i.e. the peptides/proteins present in the venom). Our interest in these studies originates in the fact that among the small number (~100-200) of proteins in snake venoms are toxins (SV-Klks, Snake Venom Klks), which display sequence homology to human KLK proteases. We use cDNA libraries from the viper snake *Sistrurus catenatus* (provided by Prof RM Kini, University of Singapore).



*Sistrurus catenatus edwardsii* Rare species


### Types of toxins

- Neurotoxins (Cobras and Coral Snakes)  
fast action, paralysis, vomiting, hypersalivation etc
- Hemotoxins (Vipers)  
slow action, internal/external bleeding, pain
- Myotoxins (Sea snakes)  
muscle destruction, pain



*Ophiophagus hannah* (king cobra)


Pahari S, Mackessy SP, Kini RM. BMC Mol Biol. 8: 15, 2007  
Fry BG et al. Mol Cell Proteomics. 7: 215-46, 2008  
Fry BG. Genome Res. 15: 403-420, 2005



In particular, our group is interested in the identification of the repertoire of toxins present in the venom of *Vipera ammodytes meridionalis*, the viper snake indigenous in Greece that is responsible for the highest number and most serious and life-threatening envenomations.



*Vipera ammodytes* is indigenous venomous snake that was collected near Patras Univ. The venom gland transcriptome and venome (venom proteome) are integrated to identify and isolate novel toxins, "leads" for drug discovery and development.



## Why studying the venome?

### 1. To discover new specific anti-venom therapies.

Current therapies rely on administration of antivenoms generated by immunizing large animals, which involve risk of allergic reactions, and different venom constituents exhibit variant immunogenicity. Anti-venoms contain numerous antibodies against weak or non-toxin components that dilute their effectiveness. As a result, large antivenom volumes are used further increasing the probability of adverse effects.


### 2. To identify novel Klk-like toxins.

Remarkably, small amino acid substitutions in enzymes found in venom result in enhanced catalytic activities compared to their ancestor physiological enzymes, to potentiate their lethal function. In the top right figure (adapted from Aminetzach et al. Curr Biol 19: 1925-1931, 2009), sequence and 3D structure comparisons revealed specific insertions or deletions in the mammalian blarina toxin, conferring structural alterations that often render venom toxins unusually active enzymes. It is expected that analogous substitutions have occurred in snake venom toxins. We seek to isolate novel SV-Klks (namely serine proteases with homology to human KLKs but with enhanced enzymatic activity) and to characterize their enzymatic activity and structure with the aim to identify structural features associated with enhanced KLK protease activity. The ultimate purpose is to produce recombinant toxins of pharmacological interest and to aid the design/optimization of potent KLK inhibitors.



## THERANOSTICS: Development and validation of activity based probes for serine proteases for dual applications as molecular diagnostics and candidate drug compounds (LMW protease inhibitors)

Often drugs fail at late stages of development because, although the drug target is indeed overexpressed in a disease state, it could occur in the inactive form due to inefficient activation or inactivation by inhibitors. Classical proteomic and gene expression approaches can identify overexpressed proteins/enzymes but fail to identify their “in situ” (at the site targeted by the drug) enzymatic activities implicated in pathology. Proteases, in particular, are popular drug targets in multiple disorders (cancer, neurodegeneration, skin diseases, cardiovascular diseases *etc*) with many examples of widely used marketed drugs targeting proteases ([Drag and Salvesen Nat Rev Drug Discov 9: 690-701, 2010](#); [Turk B. Nat Rev Drug Discov 5:785-799, 2006](#); [Sotiropoulou and Pampalakis Trends Pharmacol Sci 33: 623-634, 2012](#)). For the last 20 years, we have extensively studied and contributed to the delineation of the role of the group of serine proteases named kallikrein-related peptidases, in breast cancer, in skin disorders associated with aberrant desquamation and inflammation, and in Parkinson’s Disease. It is known that proteases are regulated at multiple from gene expression to posttranslational modification (*i.e.* production of inactive zymogens, internal cleavage and in-/de-activation, inactivation by complex formation with their endogenous inhibitors). Thus, the fraction of the active protease molecules in certain (patho)physiological states remains elusive. We have developed specific activity-based probes (ABPs) as tools for *in vitro* and *in vivo* labeling of active enzymes. For proof-of-concept we have focused on selected serine proteases (KLKs) and their activity mapping in skin disorders. We have designed and chemically synthesized ABPs with specificity for the KLK enzymes, which accommodate dual properties in the same scaffold so that they can be used: [1] as molecular diagnostics (activity reporters) and [2] as inhibitors representing potential therapeutics (theranostics). These new ABP molecules are characterized *in vitro*, used to develop new diagnostic assays, and validated for their effectiveness in protease targeting and their theranostic action in novel preclinical mouse models for skin inflammatory diseases that we have generated and characterized.



A, The structure of an organophosphonofluoridate ABP (B24P) synthesized by us. Red color shows the reactive group, black the spacer and blue the biotin detection tag ([Pampalakis et al. Chem Commun 53:3246-3248, 2017](#)). B, Schematic diagram of the activography. Briefly, biopsy cryosections are allowed to react with B24P and the overall serine protease activities are quantified with streptavidin-peroxidase chromogenic reaction.

ABPs are small organic molecules used to map various enzymatic activities (serine proteases, oxidases *etc*) in a process known as ABP profiling (ABPP). They bind to enzymes with a covalent bond formed between an electrophile on the ABP and the active-site nucleophile of the enzyme such as the catalytic serine for serine proteases ([Sanman and Bogoy, Annu Rev Biochem 83:249-273, 2014](#)). Thus, only catalytically competent proteases bind to ABP irreversibly. The ABPs consist of three parts, a reactive functional group (recognition group), a spacer and a reporter tag. Figure 1A shows the structure of an ABP we recently synthesized. The reporter is used for the detection and is adaptable to various analytical platforms (fluorescence, mass spectrometry, chromogenic reactions, *in vivo* imaging *etc*). The **great advantage of ABPs is that they report on changes in enzymatic activities, rather than total protein or mRNA abundance**. The development of ABPs is a rapidly evolving field, since they offer **unique advantages in the identification/validation of novel pharmacological targets but also in molecular diagnosis**. ABPs can be used for *in vivo* imaging of enzyme activities ([Speers et al. J Am Chem Soc 125: 4686-4687, 2003](#); [Edgington and Bogoy, Curr Protoc Chem Biol 5: 25-44, 2013](#)). A **revolutionizing application of ABPs is their use in oncological surgery** to map the tumor margins for complete dissection and to localize remaining tumor microfoci ([Cutter et al. PLoS One 7:e33060, 2012](#)). Finally, **ABPs can be easily commercialized** not only for therapeutic/diagnostic applications but also as research tools as demonstrated by the prototype ABP developed by [Liu et al. \(PNAS 96: 14694-14699, 1999\)](#) to target serine hydrolases, commercialized by Santa Cruz Biotechnology (<https://www.scbt.com/scbt/product/fp-biotin-259270-28-5>) as a new research reagent to identify active enzymes that react with organophosphates or active serine hydrolases.

## LIST OF PUBLICATIONS

### Patents

1. Sotiropoulou G, Zingkou E, University of Patras, Theracell Advanced Biotechnology, National Hellenic Research Foundation, Benaki Phytopathological Institute (2022) "Mosquito repellent composition comprising yarrow essential oil" / "Σύνθεση εντομοαπωθητικού κουνουπιών που περιλαμβάνει αιθέριο έλαιο αγραψιθιάς (yarrow)". EP22193561.2 / 01 September 2022 / 370222
2. Sotiropoulou G, Pampalakis G, Bissyris E. (2018) "Theranostic inhibitors and activity-based probes for the KLK7 protease" Patent Application Nr: 2018010052/16/11/2018.
3. Hovnanian A, Sotiropoulou G, Pampalakis G, Furio L. (2014) "Methods and pharmaceutical compositions for the treatment of Netherton syndrome". Application Nr: EP14153629.2 (03 Feb 2014), Priority date: 2014-02-03; Filing date: 2015-02-02; Publication date: 2015-08-06, WO2015114144A1, <https://patents.google.com/patent/WO2015114144A1/en?q=klk5&q=inhibitors>
4. Anisowicz A, Sager R, Sotiropoulou G. (1998) "Human protease M, a novel serine protease, and its cDNA sequence and diagnostic and therapeutic uses". PCT Int. Patent, WO 98/11238, 1-92.
5. Sotiropoulou G, Anisowicz A, Sager R. (1997) "Human cystatin M cDNA sequence, recombinant vector, gene regulation in tumor, and cancer diagnosis and therapy". PCT Int. Patent, WO 97/14797, 1-67.

### Invited Chapter

6. Pampalakis G, **Sotiropoulou G.\*** (2012) Pharmacological targeting of the human tissue kallikrein-related peptidases. In "Proteinases as Drug Targets", Edited by Ben M. Dunn, Royal Society of Chemistry, UK, RSC Publishing.

\*Corresponding author

### Published Articles

7. Chatzidaki MD, Demisli S, Zingkou E, Liggri PGV, Papachristos DP, Balatsos G, Karras V, Nallet F, Michaelakis A, **Sotiropoulou G**, Zographos SE, Papadimitriou V. (2022) Essential oil-in-water microemulsions for topical application: structural study, cytotoxic effect and insect repelling activity. Colloids Surf 654: 130159.
8. **Sotiropoulou G\***, Zingkou E, Pampalakis G.\* (2022) Novel specific activity-based probes validate KLK proteases as druggable targets. Cancer Biol Ther 23: 401-403.
9. Zingkou E, Pampalakis G, **Sotiropoulou G.\*** (2022) Cocktails of KLK5 protease inhibitors and anti-TNFα therapeutics: an effective treatment for Netherton syndrome. J Clin Immunol 42: 597-605.
10. **Sotiropoulou G\***, Zingkou E, Pampalakis G.\* (2022) Reconstructing the epidermal proteolytic cascades in health and disease. J Pathol 257: 545-560. doi: 10.1002/path.5888. Epub 2022 Apr 6.
11. **Sotiropoulou G\***, Zingkou E, Bissyris E, Pampalakis G.\* (2022) Activity-based probes for proteases pave the way to theranostic applications. Pharmaceutics 14: 977.
12. Pampalakis G\*, Angelis G, Zingkou E, Vekrellis K, **Sotiropoulou G.\*** (2022) A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis. Clin Transl Med 12(1):e657. doi: 10.1002/ctm2.657.
13. Zingkou E\*, Pampalakis G, **Sotiropoulou G.\*** (2022) Keratinocyte differentiation and proteolytic pathways in skin (patho)physiology. Int J Dev Biol 66(1-2-3): 269-275.

14. Pampalakis G\*, Zingkou E, Panagiotidis C, **Sotiropoulou G.\*** (2021) Kallikreins emerge as new regulators of viral infections. *Cell Mol Life Sci* 78: 6735-6744.
15. Bisyris E, Zingkou E, Kordopati GG, Matsoukas M, Magriotis PA, Pampalakis G, **Sotiropoulou G.\*** (2021) Generation of a quenched phosphonate activity-based probe for labelling the active KLK7 protease. *Org Biomol Chem* 19: 6834-6841.
16. Bisyris E, Zingkou E, Kordopati GG, Matsoukas M, Magriotis PA, Pampalakis G\*, **Sotiropoulou G.\*** (2021) A novel theranostic activity-based probe targeting kallikrein 7 for the diagnosis and treatment of skin diseases. *Chem Commun (Camb)* 57: 6507-6510.
17. Nauroy P, Zingkou E, **Sotiropoulou G**, Kiritsi D. (2021) Research in practice: Towards deciphering the role of epidermal proteases in recessive dystrophic epidermolysis bullosa progression. *J Dtsch Dermatol Ges* 19: 828-832.
18. **Sotiropoulou G\***, Zingkou E, Pampalakis G.\* (2021) Redirecting drug repositioning to discover innovative cosmeceuticals. *Exp Dermatol* 30: 628-644.
19. Pampalakis G, Zingkou E, Zoumpourlis V, **Sotiropoulou G.\*** (2021) Ectopic expression of KLK6 in MDA-MB-435 melanoma cells reduces tumorigenicity *in vivo*. *Pathol Res Pract* 217: 153276.
20. Angelis G, Kordopati GG, Zingkou E, Karioti A, **Sotiropoulou G**, Pampalakis G. (2021) Plausible emergence of biochemistry in enceladus based on chemobrionics. *Chemistry* 27: 600-604.
21. Sykioti SV, Karampetsou M, Chalatsa I, Polissidis A, Michael IP, Pagaki-Skaliora M, Nagy A, Emmanouilidou E, **Sotiropoulou G**, Vekrellis K. (2021) Deficiency of the serine peptidase kallikrein 6 does not affect the levels and the pathological accumulation of  $\alpha$ -synuclein in mouse brain. *J Neurochem* 157: 2024-2038.
22. Zingkou E, Pampalakis G, **Sotiropoulou G.\*** (2020) Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome. *Biochim Biophys Acta Mol Basis Dis* 1866: 165831.
23. Zingkou E, Pampalakis G, **Sotiropoulou G.\*** (2020) Exacerbated dandruff in the absence of kallikrein-related peptidase 5 protease. *J Dermatol* 47: 311-313.
24. Chen H, Sells E, Pandey R, Abril ER, Hsu CH, Krouse RS, Nagle RB, Pampalakis G, **Sotiropoulou G**, Ignatenko NA. (2019) Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein. *Oncotarget* 10: 6062-6078.
25. Pampalakis G, Zingkou E, Kaklamanis L, Spella M, Stathopoulos GT, **Sotiropoulou G.\*** (2019) Elimination of KLK5 inhibits early skin tumorigenesis by reducing epidermal proteolysis and reinforcing epidermal microstructure. *Biochim Biophys Acta Mol Basis Dis* 1865: 165520.
26. Zingkou E, Pampalakis G, Charla E, Nauroy P, Kiritsi D, **Sotiropoulou G.\*** (2019) A proinflammatory role of KLK6 protease in Netherton syndrome. *J Dermatol Sci* 95: 28-35.
27. Pampalakis G, Zingkou E, Sidiropoulos KG, Diamandis EP, Zoumpourlis V, Yousef GM, **Sotiropoulou G.\*** (2019) Biochemical pathways mediated by KLK6 protease in breast cancer. *Mol Oncol* 13: 2329-2343.
28. Zingkou E, Pampalakis G, Kiritsi D, Valari M, Jonca N, **Sotiropoulou G.\*** (2018) Activography reveals aberrant proteolysis in desquamating diseases of differing backgrounds. *Exp Dermatol* 28: 86-89.
29. Khoury N, Zingkou E, Pampalakis G, Zoumpourlis V, **Sotiropoulou G.\*** (2018) KLK6 protease accelerates skin tumor formation and progression. *Carcinogenesis* 39: 1529-1536.
30. Pampalakis G, Zingkou E, Sotiropoulou G.\* (2018) KLK5, a novel potential suppressor of vaginal carcinogenesis. *Biol Chem* 399: 1107-1111.



31. Devetzi M, Goulielmaki M, Khoury N, Spandidos DA, **Sotiropoulou G**, Christodoulou I, Zoumpourlis V. (2018) Genetically-modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)-based targeted therapy (Review). *Int J Mol Med* 41: 1177-1186.
32. Pampalakis G\*, Zingkou E, Vekrellis K, **Sotiropoulou G.\*** (2017) "Activography": a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ. *Chem Commun (Camb)* 53: 3246-3248.
33. Pampalakis G, Kiritsi D, Zingkou E, Valari M, **Sotiropoulou G.\*** (2017) Enhanced proteolytic activities in Acral Peeling Skin Syndrome: A role of transglutaminase 5 in epidermal homeostasis. *J Invest Dermatol* 137: 1808-1811.
34. Pampalakis G\*, **Sotiropoulou G.\*** (2017) Insights into the regulation of proteolytic pathways in skin differentiation. *Br J Dermatol* 176: 1433-1434.
35. Pampalakis G, Sykioti V-S, Ximerakis M, Stefanakou-Kalakou I, Melki R, Vekrellis K\*, **Sotiropoulou G.\*** (2016) KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. *Oncotarget* 8: 14502-14515.
36. Sidiropoulos KG, Ding Q, Pampalakis G, White NMA, Boulos P, **Sotiropoulou G\***, Yousef GM\* (2016) KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. *Mol Oncol* 10: 993-1007.
37. Furio L, Pampalakis G, Michael IP, Nagy A, **Sotiropoulou G\***, Hovnanian A.\* (2015) Elimination of KLK5 reverses the hallmarks of Netherton syndrome. *PLoS Genet* 11(9):e1005389.
38. Pampalakis G, Politi AL, Papanastasiou A, **Sotiropoulou G.\*** (2015) Distinct cholesterologenic and lipidogenic gene expression patterns in ovarian cancer-A new pool of biomarkers. *Genes Cancer* 6: 472-479.
39. Pasic MD, **Sotiropoulou G**, Yousef GM. (2015) The miRNA-Kallikrein interactions: adding a new dimension. *Cell Cycle* 14: 691-692.
40. Sidiropoulos KG, White NMA, Bui A, Ding Q, Boulos P, Pampalakis G, Khella H, Samuel JN, **Sotiropoulou G**, Yousef GM. (2014) Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. *Oncoscience* 1: 709-724.
41. Ximerakis M, Pampalakis G, Roumeliotis TI, Sykioti V-S, Garbis SD, Stefanis L, **Sotiropoulou G**, Vekrellis K. (2014) Resistance of naturally secreted alpha-synuclein to proteolysis. *FASEB J* 28: 3146-3158.
42. Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, **Sotiropoulou G.\*** (2014) The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. *Oncotarget* 5: 2390-2403.
43. **Sotiropoulou G\***, Pampalakis G.\* (2012) Targeting the kallikrein-related peptidases for drug development. *Trends Pharmacol Sci* 33: 623-634.
44. **Sotiropoulou G\***, Pampalakis G, Prosnikli E, Evangelatos GP, Livaniou E. (2012) Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6. *Chem Cent J* 6: 148.
45. Chimonidou M, Tzitzira A, Strati A, **Sotiropoulou G**, Sfikas C, Malamos N, Georgoulis V, Lianidou E. (2012) CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. *Clin Biochem* 46: 235-240.
46. Kapasa M, Vlachakis D, Kostadima M, **Sotiropoulou G**, Kossida S. (2012) Towards the elucidation of the regulatory network guiding the insulin producing cells' differentiation. *Genomics* 100: 212-221.

47. Arnold S, Pampalakis G, Kantiotou K, Silva D, Cortez C, Missailidis S, **Sotiropoulou G.\*** (2012) One round of SELEX for the generation of DNA aptamers directed against KLK6. *Biol Chem* 393: 343-353.
48. Papanastasiou AD, Pampalakis G, Katsaros D, **Sotiropoulou G.\*** (2011) Netrin-1 overexpression is predictive of ovarian malignancies. *Oncotarget* 2: 363-367.
49. Chimonidou M, Strati A, Tzitzira A, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. (2011) DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. *Clin Chem* 57: 1169-1177.
50. Pavlopoulou A, Pampalakis G, Michalopoulos I, **Sotiropoulou G.\*** (2010) Reconstruction of the evolutionary history of tissue kallikreins. *PLoS ONE* 5: e13781-13781.
51. Lianidou ES, Mavroudis D, **Sotiropoulou G**, Aggelaki S, Pantel K. (2010) What's new on Circulating Tumor Cells? A meeting report. *Breast Cancer Res* 12: 307-311.
52. **Sotiropoulou G\***, Pampalakis G\*. (2010) Evolving concepts of tissue kallikrein-related peptidases as bridges of immune function and proteolytic destruction of extracellular matrix. *Biol Chem* 391: 321-331.
53. Pampalakis G, Diamandis EP, Katsaros D, **Sotiropoulou G.\*** (2010) Down-regulation of Dicer mRNA in ovarian cancer tissues provides a new potential biomarker. *Clin Biochem* 43: 324-327.
54. **Sotiropoulou G\***, Pampalakis G, Diamandis EP. (2009) Functional roles of human kallikrein-related peptidases. *J Biol Chem* 284: 32989-32994.  
Reappeared *In* the JBC Thematic Minireview Series: Proteolytic Enzymes for the JBC 106<sup>th</sup> Anniversary, [http://www.jbc.org/site/thematics/proteolytic\\_enzymes/](http://www.jbc.org/site/thematics/proteolytic_enzymes/)
55. Kioulafa M, Balkouranidou I, **Sotiropoulou G**, Kaklamanis L, Mavroudis D, Georgoulas V, Lianidou ES. (2009) Methylation of cystatin M promoter in breast cancer is associated with unfavorable prognosis. *Int J Cancer* 125: 2887-2892.
56. **Sotiropoulou G\***, Pampalakis G, Lianidou ES, Mourelatos Z. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. *RNA* 15: 1443-1461. [IF=4.656]
57. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, **Sotiropoulou G.\*** (2009) A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. *Cancer Res* 69: 3779-3787.
58. **Sotiropoulou G\***, Sommerhoff CP. (2008) Highlight on advances in proteolysis research. *Biol Chem* 389: 967-969.
59. Pampalakis G, Scorilas A, **Sotiropoulou G.\*** (2008) Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. *Clin Biochem* 41: 591-597.
60. Pampalakis G, Arampatzidou M, Amoutzias G, Kossida S, **Sotiropoulou G.\*** (2008) Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates. *Comput Biol Chem* 32: 111-121.
61. Borgoño CA, Gavigan JA, Alves J, Bowles B, Harris JL, **Sotiropoulou G**, Diamandis EP. (2007) Defining the extended substrate specificity of kallikrein 1-related peptidases. *Biol Chem* 388: 1215-1225.
62. Pampalakis G, **Sotiropoulou G.\*** (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. *BBA Rev Cancer* 1776: 22-31.
63. Borgoño C, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, **Sotiropoulou G**, Blaber M, Diamandis EP. (2007) A potential role for multiple tissue kallikrein serine proteases in

epidermal desquamation: Regulation by lympho-epithelial Kazal-type inhibitor and digestion of desmoglein 1. *J Biol Chem* 282: 3640-3652.

64. Shaw JLV, Grass L, **Sotiropoulou G**, Diamandis EP. (2007) Development of an immune fluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. *Clin Biochem* 40: 104-110.
65. Pampalakis G, Arampatzidou M, **Sotiropoulou G.\*** (2006) Computational cloning and analysis of human kallikrein 6 orthologue genes. *Lect Series Comp Comput Sci* 7: 1074-1077.
66. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, **Sotiropoulou G**, Diamandis EP. (2006) Human tissue kallikrein 5 (hK5) is a member of a proteolytic cascade involved in seminal clot liquefaction and potentially in prostate cancer progression. *J Biol Chem* 281: 12743-12750.
67. Pampalakis G\*, Diamandis EP, **Sotiropoulou G.\*** (2006) The epigenetic basis for the aberrant expression of kallikreins in human cancers. *Biol Chem* 387: 795-799.
68. Pampalakis G, **Sotiropoulou G.\*** (2006) Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. *Biol Chem* 387: 773-782.
69. Lundwall Á, Band V, Blaber M, Clements J, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, **Sotiropoulou G**, Stenman U-H, Stephan C, Talieri M, Yousef GM. (2006) A comprehensive nomenclature for serine proteases with homology to the tissue kallikrein. *Biol Chem* 387: 637-641.
70. Michael IP, **Sotiropoulou G**, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. *J Biol Chem* 280: 14628-14635.
71. Sidiropoulos M, Pampalakis G, **Sotiropoulou G**, Katsaros D, Diamandis EP (2005) Down-Regulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. *Tumor Biol* 26: 324-336.
72. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, **Sotiropoulou G**, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP. (2005) Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. *Clin Chem* 51: 1432-1442.
73. Pampalakis G, Kurlender L, Diamandis EP, **Sotiropoulou G.\*** (2004) Cloning and characterization of novel isoforms of the human kallikrein 6 gene. *Biochem Biophys Res Commun* 320: 54-61.
74. Bayés A, Tsetsenis T, Ventura S\*, Avilés FX, Vendrell J, **Sotiropoulou G.\*** (2004) Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. *Biol Chem* 385: 517-524.
75. Shridhar R, Zhang J, Song J, Booth BA, Kevil CG, **Sotiropoulou G**, Sloane BF, Keppler D. (2004) Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. *Oncogene* 23: 2206-2215.
76. Ghosh MC, Grass L, Soosaipillai A, **Sotiropoulou G**, Diamandis EP. (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. *Tumor Biol* 25: 193-199.
77. Magklara A, Mellati AA, Wasney GA, Little SP, **Sotiropoulou G**, Becker GW, Diamandis EP. (2003) Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. *Biochem Biophys Res Commun* 307: 948-955.
78. **Sotiropoulou G\***, Rogakos V, Tsetsenis T, Pampalakis G, Zafeiropoulos N, Simillides G, Yiotakis A, Diamandis EP. (2003) Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. *Oncol Res* 13: 381-391.

79. Kapadia C, Chang A, **Sotiropoulou G**, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DHC, Diamandis EP. (2003) Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. *Clin Chem* 49: 77-86.
80. Gomis-Rüth FX, Bayés A, **Sotiropoulou G**, Pampalakis G, Tsetsenis T, Vigellas V, Avilés FX, Coll M. (2002) The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. *J Biol Chem* 277: 27273-27281.
81. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, **Sotiropoulou G**, Diamandis EP, Hudson TJ, White JH. (2002) Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D<sub>3</sub> analog EB1089 signalling on cell proliferation, differentiation, and immune system regulation. *Mol Endocrinol* 16: 1243-1256.
82. **Sotiropoulou G\***, Kono M, Anisowicz A, Stenman G, Tsuji S, Sager R. (2002) Identification and functional characterization of a human GalNAc  $\alpha$ 2,6-sialyltransferase with altered expression in breast cancer. *Mol Med* 8: 42-55.
83. Zeeuwen PL, Van Vlijmen-Willems IM, Jansen BJ, **Sotiropoulou G**, Curfs JH, Meis JF, Janssen JJ, Van Ruissen F, Schalkwijk J. (2001) Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase. *J Invest Dermatol* 116: 693-701.
84. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, **Sotiropoulou G**. (2000) Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. *Clin Biochem* 33: 369-375.
85. Dionyssopoulou H, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis P, **Sotiropoulou G.\*** (2000) Synthetic peptides as putative therapeutic agents in transplantation medicine: application of PEPSCAN to the identification of functional sequences in the extracellular domain of the interleukin-2 receptor beta chain (IL-2Rbeta). *J Immunol Meth* 241: 83-95.
86. Yousef GM, Luo LY, Scherer SW, **Sotiropoulou G**, Diamandis EP. (1999) Molecular characterization of zyme/protease M/neurosin, a hormonally-regulated kallikrein-like serine protease. *Genomics* 62: 251-259. [IF=3.386]
87. Anisowicz A, **Sotiropoulou G**, Sager R. (1999) Re-expression of the SPR1 gene in breast carcinomas by phorbol 12-myristate 13-acetate or UV irradiation is mediated by the AP-1 binding site in the SPR1 promoter. *Mol Med* 5: 526-541.
88. **Sotiropoulou G**, Anisowicz A, Sager R. (1997) Identification, cloning and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. *J Biol Chem* 272: 903-910.
89. Stenman G, Astrom AK, Roijer E, **Sotiropoulou G**, Zhang M, Sager R. (1997) Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence *in situ* hybridization. *Cytogen Cell Genet* 76: 45-46. [IF=2.469]
90. Anisowicz A, **Sotiropoulou G**, Stenman G, Mok SC, Sager R. (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. *Mol Med* 2: 624-636. [IF=3.972]
91. Sager R, Sheng S, Anisowicz A, **Sotiropoulou G**, Zou Z, Swisshelm K, Hendrix M, Thor A, Ryan K, Rafidi K, Seftor E. (1994) RNA genetics of breast cancer: maspin as a paradigm. *CSHL Quant Biol* 59: 537-546.
92. Sager R, Anisowicz A, Neveu M, Liang P, **Sotiropoulou G**. (1993) Identification by differential display of alpha 6 integrin as a candidate tumor suppressor gene. *FASEB J* 7: 964-970.

93. Drakopoulou E, **Sotiropoulou G**, Tsilivakos V, Georgoulas V, Cordopatis P. (1994) Synthetic peptides from the region 30-54 of the interleukin-2 receptor  $\beta$ -chain (IL-2R $\beta$ ) affect IL-2 binding to human T-cells. *Coll Czech Chem Commun* 59: 943-950.
94. Burnap R, Koike H, **Sotiropoulou G**, Sherman LA, Inoue Y. (1989) Oxygen evolving membranes and particles from the transformable cyanobacterium *Synechocystis* sp. PCC 6803. *Photosynth Res* 22: 123-130.
95. Papageorgiou GC, Kalosaka K, **Sotiropoulou G**, Barbotin JN, Thomasset B, Thomas D. (1988) Entrapment of active ion-permeable cyanobacteria (*Anacystis nidulans*) in calcium alginate. *Appl Microbiol Biotechnol* 29: 565-571.
96. **Sotiropoulou G**, Papageorgiou GC. (1986) Stimulation and inhibition of photosystem II electron transport in cyanobacteria by ions interacting with the cytoplasmic face of thylakoids. *Photosynth Res* 10: 445-450.
97. Kalosaka K, **Sotiropoulou G**, Papageorgiou GC. (1985) Retardation of electron donation to Photosystem I in aged cyanobacteria and its reversal by metal cations. *Biochim Biophys Acta* 808: 273-279.
98. Pampalakis G, **Sotiropoulou G.\*** (2003) Pharmacological modulation of protease M in metastatic breast tumors by DNA demethylation. *Eur J Drug Metab Pharmacok* 28: 23.
99. Pampalakis G, Tsetsenis T, Zafeiropoulos N, Diamandis EP, **Sotiropoulou G.\*** (2003) Human kallikreins as cancer biomarkers. *Eur J Drug Metab Pharmacok* 28: 31.

## Book Chapters

100. Mouzaki A, Dionyssopoulou H, **Sotiropoulou G**, Cordopatis P, Slootstra J, Puijk W, Meloen R, Maniatis A. (1999) Synthetic peptides as putative therapeutic agents in transplantation medicine: Identification of epitopes on the extra cellular domain of the beta chain of the interleukin-2 receptor. *Biomed and Health Res Ser* 22: 181-193.
101. Drakopoulou E, **Sotiropoulou G**, Tsilivakos V, Perraki M, Georgoulas V, Cordopatis P. (1995) In vitro effects of synthetic peptides homologous to the  $\beta$  (p70) chain of interleukin-2 receptor on the binding of the interleukin-2. *Rev Clin Pharmacol Pharmacok* 9: 93-94.
102. Drakopoulou E, **Sotiropoulou G**, Tsilivakos V, Georgoulas V, Cordopatis P. (1992) Synthetic peptides from the IL-2R $\beta$  sequence (30-54) affect the interleukin-2 (IL-2) binding. *Peptides 1992* (C. H. Schneider, ed.), ESCO.
103. **Sotiropoulou G**, Papageorgiou GC. (1987) Functional interactions of anions and cations with the outer surface of intact thylakoids: studies with the blue-green cyanobacterium *Anacystis nidulans*. *Progress in Photosynthesis Research* 2: 785-788.
104. Papageorgiou GC, **Sotiropoulou G**, Lagoyanni T, Kalosaka K. (1986) Electrolyte control of photosynthetic electron transport in cyanobacteria. In: *Creation and Deactivation of Excited States of Biological Molecules* (Frackowiak D, ed), 11-16, Polish Academy of Sciences, Poznan Polytechnic.
105. **Sotiropoulou G**, Papageorgiou GC. (1985) Modulation of the Hill reaction rates by ions interacting with the outer surface of cyanobacterial thylakoids. In: *Ion Interactions in Energy Transfer Biomembranes* (Papageorgiou GC, Barber J, Papa S, eds), 303-312, Plenum Press, New York.
106. Papageorgiou GC, Kalosaka K, Lagoyanni T, **Sotiropoulou G**. (1985) The role of cations in the photoinduced electron transport of cyanobacteria. *Recent Advances in Biological Membrane*

Studies: Structure and Biogenesis, Oxidation and Energetics (Packer L, ed), 369-391, Academic Press, New York.

107. **Sotiropoulou G**, Lagoyanni T, Papageorgiou GC. (1984) Effects of  $\text{Ca}^{2+}$  ions on the light-induced electron transport activities of *Anacystis nidulans* permeoplasts and spheroplasts. Adv Photosynth Res 2: 663-666.

## ORIGINAL SEQUENCE SUBMISSIONS [GenBank™/EMBL]

National Center for Biotechnology Information: <http://www.ncbi.nlm.nih.gov>

**GenBank™/EMBL:** 11 (U62800, U62801, U14550, AY318867, AY318868, AY318869, AY318870, AY457039, AF079516, AY804248, DQ223012)

**PDB** : 1 (1GVL)

1. DQ641251: Homo sapiens new PSA transcript variant, mRNA, partial cds  
1221 bp mRNA linear (Direct Submission: 16-MAY-2006)  
Pampalakis G, **Sotiropoulou G**. Identification of new PSA isoform.
2. DQ223012: Homo sapiens kallikrein 6 precursor (KLK6)  
(Direct Submission: 26-SEP-2005) mRNA, complete cds, alternatively  
transcript variant 3. LOCUS: DQ223012, 842 bp mRNA linear  
Pampalakis G, **Sotiropoulou G**. Identification of a novel KLK6 transcript variant
3. AY804248: Homo sapiens kallikrein 6 (KLK6) gene, 5' flanking region  
LOCUS: AY804248, 319 bp DNA linear  
**Sotiropoulou G**, Pampalakis G. (Direct Submission: 27-OCT-2004)
4. AY457039: Homo sapiens kallikrein 6-like mRNA, complete cds  
**Pampalakis G**, Sotiropoulou G. Cloning of novel transcript variants of human  
kallikrein 6/protease M/zyme/neurosin gene (KLK6)
5. AY318867: Homo sapiens kallikrein 6 precursor (KLK6) mRNA, complete cds  
LOCUS: AY318867, 1517 bp mRNA linear (Direct Submission: 09-JUN-2003)  
Pampalakis G, Diamandis EP, **Sotiropoulou G**. Cloning of novel transcript variants  
of the human kallikrein 6/protease M/zyme/neurosin gene (KLK6)
6. AY318868: Homo sapiens kallikrein 6-like mRNA, complete sequence  
LOCUS: AY318868, 820 bp mRNA linear (Direct Submission: 10-JUN-2003)  
Pampalakis G, Diamandis EP, **Sotiropoulou G**. Cloning of novel transcript variants of  
the human kallikrein 6/protease M/zyme/neurosin gene (KLK6)
7. AY318869: Homo sapiens kallikrein 6 precursor (KLK6) mRNA, complete cds  
LOCUS: AY318869, 1503 bp mRNA linear (Direct Submission: 09-JUN-2003)  
Pampalakis G, Diamandis EP, **Sotiropoulou G**. Cloning of novel transcript variants of  
the human kallikrein 6/protease M/zyme/neurosin gene (KLK6)
8. AY318870: Homo sapiens kallikrein 6-like mRNA, complete sequence  
LOCUS: AY318870, 929 bp mRNA linear (Direct Submission: 10-JUN-2003)  
Pampalakis G, Diamandis EP, **Sotiropoulou G**. Cloning of novel transcript variants  
of the human kallikrein 6/protease M/zyme/neurosin gene (KLK6)
9. NM002774: Homo sapiens kallikrein 6 (neurosin, zyme) (KLK6), mRNA



LOCUS: NM002774, 1512 bp, mRNA linear

Gomis-Ruth FX, Bayes A, **Sotiropoulou G**, Pampalakis G, Tsetsenis T, Villegas V, Aviles FX, Coll M. (2002)

10. U14550: Human sialyltransferase SThM (*sthm*) mRNA, complete cds.  
Locus: HSU14550, 1908 bp, mRNA (Direct Submission: 07-NOV-1994)  
**Sotiropoulou G**, Anisowicz A, Sager R. (1994) Isolation and cloning from human mammary epithelial cells of a complete cDNA sequence homologous to other known sialyltransferases.
11. U62800: Homo sapiens cystatin M (CST6) mRNA, complete cds  
Locus: HSU6280, 577 bp mRNA  
**Sotiropoulou G**, Anisowicz A, Sager R. (Direct Submission: 02-JUL-1996)
12. U62801: Human Protease M mRNA, complete cds  
Locus: HSU62801, 1506 bp mRNA  
Anisowicz A, **Sotiropoulou G**, Sager R. (Direct Submission: 02-JUL-1996)
13. AF079516: Homo sapiens small proline-rich protein 1 (SPR1), promoter region.  
Locus: AF079516, 634 bp DNA  
Anisowicz A, **Sotiropoulou G**, Sager R. (Direct Submission: 21-JUL-1998)

#### **PDB Database**

##### **14.1GVL\_A Chain A, Human Prokallikrein 6 (hK6) Prozyme Proprotease M Proneurosin**

LOCUS: 1GVL\_A, 223 aa PDB: molecule 1GVL (Method: X-ray Diffraction)

Gomis-Ruth FX, Bayés A, **Sotiropoulou G**, Pampalakis G, Tsetsenis T, Vigellas V, Avilés FX, Coll M. (Direct Submission: 14-Feb-2002)

## SELECTED PRESENTATIONS IN INTERNATIONAL SCIENTIFIC CONFERENCES (1994-selected)

1. Nauroy P, Zingkou E, Athanasiou I, Dengjel J, Sotiropoulou G, Nyström A, Kiritsi D. (2020) Kallikrein 6, an epidermally secreted protease, contributes to inflammation and fibrosis during Recessive Dystrophic Epidermolysis Bullosa disease progression. *Matrix Biology Europe Congress 2020 (MBE2020)*, Florence, Italy, 24-28 May 2020
2. Kordopati GG, Zingkou E, Angelis G, Stefanis I, Karioti A, Bilia A-R, Tsiftoglou O, Chafouz R, Lazari D, Vekrellis K, Magriotis P, Sotiropoulou G, Pampalakis G. (2020) Identification of new phytochemicals that inhibit  $\alpha$ -synuclein fibrilization to prevent or delay the progression of Parkinson disease. *20<sup>th</sup> International Congress of the International Society for Ethnopharmacology*, 27-29 April 2020, Capsis Hotel, Thessaloniki, Greece
3. Pampalakis G, Sykioti V-S, Ximerakis M, Melki R, Vekrellis K, Sotiropoulou G. (2017) KLK6 represses alpha-synuclein prion-like propagation with potential pharmacological applications. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
4. Sotiropoulou G. (2017) Role of KLKs in the regulation of immune function. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
5. Pampalakis G, Zingkou E, Valari M, Kiritsi D, Jonca N, Sotiropoulou G. (2017) Activography: A novel, versatile and easily adaptable histochemical method for monitoring enzymatic activities. Validation in biopsy specimens. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
6. Zingkou E, Pampalakis G, Sotiropoulou G. (2017) Effective therapy for Netherton syndrome requires combined targeting of KLK5 and TNF $\alpha$ . *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
7. Pampalakis G, Zingkou E, Charla E, Jonca N, Schilling O, Sotiropoulou G. (2017) Delineation of the role of the KLK5 protease in Peeling Skin Disease. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
8. Zingkou E, Pampalakis G, Charla E, Sotiropoulou G. (2017) The double knockout mouse *Spink5<sup>-/-</sup> Klk6<sup>-/-</sup>* reveals that *KLK6* is implicated in skin inflammation. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
9. Khoury N, Pampalakis G, Zingkou E, Zoumpourlis V, Sotiropoulou G. (2017) Elimination of *Klk6* inhibits the development and progression of non-melanoma skin cancer *in vivo* by suppression of skin inflammation. *The 7<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2017)*, Université F. Rabelais, Tours, France, 26-29 September 2017
10. Kiritsi D, Pampalakis G, Zingkou E, Franzke C-W, Valari M, **Sotiropoulou G**. (2017) Enhanced proteolytic activities in Acral Peeling Skin Syndrome: A role of transglutaminase 5 in epidermal homeostasis. *EB2017 - 5<sup>th</sup> World Conference of EB Research & 4<sup>th</sup> Conference of EB-CLINET*, 24-27 September 2017, Salzburg, Austria
11. Dimopoulou A, Botsakis K, **Sotiropoulou G**, Vekrellis K, Angelatou F. (2017) Increased phosphorylated (Ser129) alpha-synuclein in substantia nigra and striatum of the dopamine deficient "Weaver" mouse indicates the presence of alpha-synuclein pathology. "20 years of alpha-synuclein in Parkinson's Disease and related synucleinopathies: from the bedside to the bench and back to the patient", Athens, Vravrona (Hotel Mare Nostrum), 7-10 September 2017

12. **Sotiropoulou G**, Pampalakis G, Charla E, Zingkou E, Jonca N, Schilling O. (2017) Targeting epidermal KLK5 to rescue Peeling Skin Syndrome. *The International Society for Enzymology Annual Conference: Advances in Laboratory Medicine and Pathobiology 2017 (ISE2017)*, Santorini Palace, Flra, Thira (Santorini), Greece, June 16-19, 2017
13. Kiritsi D, Pampalakis G, Zingkou E, Franzke C-W, Valari M, **Sotiropoulou G**. (2017) Enhanced proteolytic activities in Acral Peeling Skin Syndrome: A role of transglutaminase 5 in epidermal homeostasis. *The International Society for Enzymology Annual Conference: Advances in Laboratory Medicine and Pathobiology 2017 (ISE2017)*, Santorini Palace, Flra, Thira (Santorini), Greece, June 16-19, 2017
14. Pampalakis G, Sykioti V-S, Ximerakis M, Vekrellis K, **Sotiropoulou G**. (2017) KLK6 proteolysis is implicated in the regulation of extracellular alpha-synuclein species and may represent a novel therapeutic approach. *The International Society for Enzymology Annual Conference: Advances in Laboratory Medicine and Pathobiology 2017 (ISE2017)*, Santorini Palace, Flra, Thira (Santorini), Greece, June 16-19, 2017
15. Pampalakis G, Zingkou E, Vekrellis K, **Sotiropoulou G**. "Activography": A novel, versatile and easily adaptable diagnostic method for monitoring enzymatic activities in tissues. *The 22<sup>nd</sup> Congress of the International and European Federations of Clinical Chemistry and Laboratory Medicine of Clinical Chemistry and Laboratory Medicine, IFCC-EFLM EuroMedLab2017*; [www.athens2017.org](http://www.athens2017.org)), Athens (Greece) June 11-15, 2017
16. Chen H, Sells E, Cui H, Pandey R, Doetschman T, Pampalakis G, **Sotiropoulou G**, Ignatenko NA. "Human tissue Kallikrein 6 enzyme activity regulates epithelial-mesenchymal transition in colon cancer." *The 108<sup>th</sup> Annual Meeting of the American Association for Cancer Research (AACR)*, Walter E. Washington Convention Center, Washington DC, USA, April 1-5, 2017
17. Pampalakis G, Kiritsi D, Zingkou E, Valari M, Bruckner-Tuderman L, **Sotiropoulou G**. "Elevated epidermal proteolysis and altered KLK5 expression in Acral Peeling Skin Syndrome." *The 46<sup>th</sup> Annual Meeting of the European Society for Dermatological Research*, Munich, Germany, September 7-10, 2016  
Abstract published in: *Journal of Investigative Dermatology* 136 (9): Suppl. 2, S176, 2016
18. Khoury N, Pampalakis G, Zingkou E, Zoumpourlis V, **Sotiropoulou G**.\* "KLK6 protease promotes tumor incidence and growth in skin." *The 46<sup>th</sup> Annual Meeting of the European Society for Dermatological Research*, Munich, Germany, September 7-10, 2016  
Abstract published in: *Journal of Investigative Dermatology* 136 (9): Suppl. 2, S242, 2016
19. Zingkou E, Pampalakis G, Charla H, **Sotiropoulou G**.\* "Combined targeting of skin proteolysis and inflammation as a therapeutic approach for Netherton syndrome." *The 46<sup>th</sup> Annual Meeting of the European Society for Dermatological Research*, Munich, Germany, September 7-10, 2016  
Abstract published in: *Journal of Investigative Dermatology* 136 (9): Suppl. 2, S184, 2016
20. **Sotiropoulou G**, Zingkou E, Charla H, Pampalakis G. "Rare skin syndrome provide insights and druggable targets for epidermal overdesquamation and inflammation. " "Advances in Laboratory Medicine and Pathobiology 2016". *Under the auspices of the International Society for Enzymology (ISE)*, Syros, July 1<sup>st</sup> to Monday July 4<sup>th</sup>, 2016
21. Furio L#, Pampalakis G#, Michael IP, Nagy A, **Sotiropoulou G**\*, Hovnanian A.\* "KLK5 knock-out rescues neonatal lethality and skin defects in a murine model for Netherton syndrome". 1st International Symposium Future in Dermatology: Inflammation. UCD Charles Institute of Dermatology, Dublin, Ireland, 2-3 Oct, 2015  
Abstract published in: *Experimental Dermatology* 24: 983-986, 2015

22. Furio L, Pampalakis G, Michael I, Nagy A, **Sotiropoulou G**, Hovnanian A. "KLK5 knock-out reverses cutaneous hallmarks of Netherton syndrome". *45<sup>th</sup> Annual Meeting of the European Society for Dermatological Research*, Rotterdam, The Netherlands. 9-12 September 2015.  
Abstract published in: *Journal of Investigative Dermatology* 135: S55, 2015
23. **Sotiropoulou G**. "Novel animal models for validation of KLK5 protease as a drug target for overdesquamating/inflammatory skin diseases". *1<sup>st</sup> International CRS Congress*, Aegli Zappiou, Athens, Greece, May 27-28, 2015
24. Sidiropoulos KG, White NMA, Ding Q, Boulos P, **Sotiropoulou G**, Pampalakis G, Yousef GM. "Kallikrein-related peptidase 6 regulates miR-34a and miRNA-mediated networks to affect oncogenic cell cycle pathways in breast cancer". *The 104<sup>th</sup> Annual Meeting of the United States and Canadian Academy of Pathology (USCAP)*, Hynes Convention Center, Boston, MA, USA, March 21-27, 2015  
Abstract published in: *Laboratory Investigation* 95 (S1): 4-573, 2015
25. Sidiropoulos KG, White NM, Bui A, Boulos P, Ding QC, **Sotiropoulou G**, Pampalakis G, Khella H, Yousef GM. "miRNA-mediated anti-metastatic pathway induction by kallikrein 5 over-expression in breast cancer". *The 103<sup>rd</sup> Annual Meeting of the United States and Canadian Academy of Pathology (USCAP)*, San Diego, CA, USA, March 1-7, 2014  
Abstract published in: *Laboratory Investigation* 94 (S1): 34-90, 2014
26. Pampalakis G, Zinghou E, Kalogeropoulou G, Spella M, Stathopoulos G, López-Otín C, **Sotiropoulou G**. "Dual roles of the KLK5 protease in cancer: Insights into the underlying mechanisms". *2<sup>nd</sup> Advances in Circulating Tumor Cells (ACTC): 2nd International Symposium ACTC-Advances in Circulating Tumor Cells (ACTC): From Basic Research to Clinical Practice (ACTC2014: www.actc2014.org/)*, Iberostar Creta Panorama & Mare, Rethymnon, Crete, Greece, 8-11 Oct, 2014
27. Pampalakis G, Zinghou E, Kalogeropoulou G, Spella M, Stathopoulos G, López-Otín C, **Sotiropoulou G**. "Elimination of KLK5 suppresses skin tumor formation by activating epidermal NF- $\kappa$ B". *44<sup>th</sup> Annual Meeting of the European Society for Dermatological Research (ESDR2014; http://www.esdr2014.org/KPH/)*, Copenhagen, Denmark, 10-13 Sept 2014
28. Ximerakis M, Pampalakis G, Roumeliotis T, Sykioti V-S, Garbis SD, Stefanis L, **Sotiropoulou G**, Vekrellis K. "Extracellular  $\alpha$ -synuclein is resistant to direct KLK6 proteolysis". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013  
Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014
29. Pampalakis G, Furio L, **Sotiropoulou G**, Hovnanian A. "Generation of the *Klk5*<sup>-/-</sup> mouse to investigate the roles of KLK5 in skin". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013  
Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014
30. **Sotiropoulou G**, Pampalakis G, Smith C, Papadodima O, Chatziioannou A, Zoumpourlis V, Diamandis EP. "Insights into the molecular pathways underlying the dual roles of KLK6 in breast cancer". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013  
Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014
31. Zingkou L, Pampalakis G, **Sotiropoulou G**. "Development and characterization of a new polyclonal specific for mouse *Klk6*". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-*

*related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013

Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014

32. Sidiropoulos KG, White NM, Buil A, Boulos P, Ding QC, **Sotiropoulou G**, Pampalakis G, Khella H, Yousef GM. "miRNA-mediated anti-oncogenic pathway induction by kallikrein 5 overexpression in breast cancer cell lines". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013

Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014

33. White NM, Boulos P, Sidiropoulos KG, Pampalakis G, Bui A, Ding Q, Yousef GM, **Sotiropoulou G**. "Kallikrein-related peptidase 6 in breast cancer: effect on miRNA expression and the MAPK pathway". *The 5<sup>th</sup> Annual International Symposium on Kallikreins and kallikrein-related peptidases (ISK2013)*, Li Ka Shing Knowledge Institute at Saint Michael Hospital, Toronto, Ontario, Canada, Sept 28<sup>th</sup> to Oct 1<sup>st</sup>, 2013

Abstract published in: *Clinical Chemistry and Laboratory Medicine* 52(7): eA21–eA4877, 2014

34. Ximerakis M, Pampalakis G, Roumeliotis T, Sykioti V-S, Garbis SD, Stefanis L, **Sotiropoulou G**, Vekrellis K. "Extracellular  $\alpha$ -synuclein is resistant to direct KLK6 proteolysis". *5<sup>th</sup> Conference on Advances in molecular mechanisms underlying neurological disorders-A Joint Conference of the European Society for Neurochemistry and the Biochemical Society*, Bath, UK, June 23-26, 2013

35. **Sotiropoulou G**, Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V. "KLK5 is a putative suppressor of breast cancer and may exert its effects by repressing epithelial-to-mesenchymal transitions and the mevalonate pathway". *Advances in Circulating Tumour Cells (ACTC): From Basic Research to Clinical Practice (ACTC2012)*, Astir Palace Vouliagmeni-Westin Resort, Sept 26-29, 2012

36. **Sotiropoulou G**, Pampalakis G, Smith C, Zoumpourlis V, Diamandis EP. "Molecular basis for the concentration-dependent tumor suppressing effects of KLK6 in breast cancer". *Proceedings of the 103<sup>rd</sup> Annual Meeting of the American Association for Cancer Research*, Chicago, USA, Mar 31-Apr 4, 2012

37. Pampalakis G, Osahon O, Papadodima O, Chatziioannou A, Zoumpourlis V, **Sotiropoulou G**. "Suppression of the mevalonate pathway and oncogenic signaling may underlie the tumor-suppressing effects of KLK5 in breast cancer". *Proceedings of the 103<sup>rd</sup> Annual Meeting of the American Association for Cancer Research*, Chicago, USA, Mar 31-Apr 4, 2012

38. Pampalakis G, Osahon O, Papadodima O, Chatziioannou A, Zoumpourlis V, **Sotiropoulou G**. "Biochemical pathways underlying breast cancer suppression by KLK5". *4<sup>th</sup> International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011): Biochemistry, Molecular Biology and Association to Disease*, Rhodos Palace Hotel, Rhodes Island, Greece, Sept 2-4, 2011

39. Ximerakis M, Karampetsou A, Emmanouilidou E, Pampalakis G, **Sotiropoulou G**, Karalis KP, Stefanis L, Vekrellis K. "Effects of secreted  $\alpha$ -synuclein on cellular homeostasis-a focus on glial cells". *The 23<sup>rd</sup> Biennial Meeting of the International Society of Neurochemistry and the European Society of Neurochemistry (ISN-ESN-2011)*, Athens, Greece, Aug 28-Sept 1, 2011

40. Dimitrakopoulos L, Vorkas PA, **Sotiropoulou G**, Georgoulis V, Lianidou ES. "Development of a methylation-sensitive high resolution melting assay (MS-HRMA) for cystatin C (CST6)". *21<sup>st</sup> International Congress of Clinical Chemistry and Laboratory Medicine, 19<sup>th</sup> IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine*, Berlin, Germany, May 2011

Abstract published in: *Clinical Chemistry and Laboratory Medicine* 49: Suppl. 1, S251-S2512011, 2011

41. Dimitrakopoulos L, Vorkas P, **Sotiropoulou G**, Georgoulas V, Lianidou ES. "Development of a methylation-sensitive high-resolution melting assay (MS-HRMA) for cystatin M (CST6)." *The 102<sup>nd</sup> Annual Meeting of American Association of Cancer Research (AACR)*, Orlando, FL, USA, 2011
42. Chimonidou M, Strati A, Tzitzira A, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. "DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells." *21<sup>st</sup> International Congress of Clinical Chemistry and Laboratory Medicine, 19<sup>th</sup> IFCC-EFCC European Congress of Clinical Chemistry and Laboratory Medicine*, Berlin, Germany, May 2011  
Abstract published in: *Clinical Chemistry and Laboratory Medicine* 49: Suppl. 1, S251-S251, 2011
43. Chimonidou M, Strati A, Tzitzira A, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. "DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells." *The 102<sup>nd</sup> Annual Meeting of American Association of Cancer Research (AACR)*, Orlando, FL, USA, 2011
44. **Sotiropoulou G**, Pampalakis G, Prosnikli E, Vlahou A, Agalioti T, Zoumpourlis V. "A tumor protective role of kallikrein-related peptidase 6 in breast cancer". *Nature Conferences-The Miami 2010 Winter Symposium: Targeting Cancer Invasion and Metastasis*, Deauville Beach Resort, Miami Beach, FL, USA, Feb 21-24, 2010
45. Tzitzira A, Strati A, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. "DNA methylation of the tumor suppressor gene CST6 in circulating tumor cells (CTCs) of breast cancer patients". *Nature Conferences-The Miami 2010 Winter Symposium: Targeting Cancer Invasion and Metastasis*. Deauville Beach Resort, Miami Beach, FL, USA, Feb 21-24, 2010
46. **Sotiropoulou G**, Pampalakis G, Prosnikli E, Vlahou A, Agalioti T, Zoumpourlis V. "Emerging roles of human kallikrein-related peptidase 6 in cancer". *6<sup>th</sup> General Meeting of the International Proteolysis Society (IPS2009), Workshop on Kallikreins and Other Emerging Serine Proteases in Disease*, Surfers Paradise, Gold Coast, QLD, Australia, Oct 26-31, 2009
47. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, **Sotiropoulou G**. "A tumor protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition". *7<sup>th</sup> International Symposium on Minimal Residual Cancer (7<sup>th</sup> ISMRC)*, Astir Palace Vouliagmeni, Athens, Greece, Sept 16-19, 2009
48. Tzitzira A, Kioulafa M, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. "Detection of CST6 promoter methylation in cell-free DNA circulating in plasma of operable breast cancer patients". *7<sup>th</sup> International Symposium on Minimal Residual Cancer (7<sup>th</sup> ISMRC)*, Astir Palace Vouliagmeni, Athens, Greece, Sept 16-19, 2009
49. Tzitzira A, Strati A, **Sotiropoulou G**, Malamos N, Georgoulas V, Lianidou ES. "DNA methylation of the tumor suppressor gene CST6 in circulating tumor cells (CTCs) of breast cancer patients." *7<sup>th</sup> International symposium on Minimal Residual Cancer (7<sup>th</sup> ISMRC)* Astir Palace Vouliagmeni, Athens, Greece, Sept 16-19, 2009
50. **Sotiropoulou G**. "KLK proteolytic cascade pathways in normal physiology and cancer". *3<sup>rd</sup> International Symposium on Kallikreins and Kallikrein-related Peptidases*, TUM, Munich, Germany, Aug 30-Sept 2, 2009
51. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, **Sotiropoulou G**. "Functional roles of human kallikrein-related peptidase 6 in breast cancer". *3<sup>rd</sup> International Symposium on Kallikreins and Kallikrein-related Peptidases*, TUM, Munich, Germany, Aug 30-Sept 2, 2009
52. Pavlopoulou A, Pampalakis G, **Sotiropoulou G**. "Unraveling the regulatory mechanisms of cystatin M tumor suppressor". *Proceedings of the 100<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, Denver, Colorado, USA, April 18-22, 2009 [# 09-AB-5187-AACR]
53. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, **Sotiropoulou G**. "A tumour protective role for human kallikrein 6 in breast cancer mediated by inhibition of epithelial-to-

mesenchymal transition", *EMBO Workshop on "Can epigenetics influence reprogramming and metastatic progression?"*, Banz Monastery, Bad Staffelstein, Germany, Oct 6-9, 2008

54. **Sotiropoulou G**, Pampalakis G, Arampatzidou M, Volanis D, Zoumpourlis V. "KLK6 reverses the malignant phenotype of metastatic breast cancer cells", *Proteinases and Their Inhibitors–Recent Developments*, 25<sup>th</sup> Winter School Tiers, Italy, Feb 27-Mar 2, 2008
55. Kioulafa M, Kaklamanis L, **Sotiropoulou G**, Stathopoulos E, Mavroudis D, Georgoulis V, Lianidou ES. "Prognostic significance of cystatin M (CST6) methylation status in early breast cancer". *The XVI meeting of Balcan Clinical Laboratory Federation & Hellenic Congress of Clinical Chemistry*, Athens, Greece, 16-18 October, 2008
56. Pampalakis G, Prosnikli E, Agalioti, Zoumpourlis, Vlahou A, **Sotiropoulou G**. "Protective Effects of Proteases and Inhibitors on Tumor progression: A tumor suppressor role for human kallikrein 6 in breast cancer." *The 5<sup>th</sup> General Meeting of the International Proteolysis Society*, Patras, Greece, Oct 20-25, 2007
57. Kioulafa M, Kaklamanis L, **Sotiropoulou G**, Georgoulis V, Lianidou ES. "Association of cystatin M methylation status and clinical outcome in breast cancer." *The 5<sup>th</sup> General Meeting of the International Proteolysis Society*, Patras, Greece, Oct 20-25, 2007
58. Triantafyllou P, Tsaroucha EG, Kaklamanis L, **Sotiropoulou G**, Georgoulis V, Lianidou ES. "Association of cystatin M methylation status and clinical outcome in NSCLC." *The 5<sup>th</sup> General Meeting of the International Proteolysis Society*, Patras, Greece, Oct 20-25, 2007
59. **Sotiropoulou G**. "Emerging roles of kallikreins in cancer". *New Molecules in Cancer Therapeutics*, Divany Caravel, Athens, Oct 12-14, 2007
60. Pampalakis G, Scorilas A, **Sotiropoulou G**. "Novel Splice Variants of Prostate-Specific Antigen and Applications in Diagnosis of Prostate Cancer", *6<sup>th</sup> International Symposium on Minimal Residual Cancer*, Hamburg, Germany, Sept 19-22, 2007
61. Kioulafa M, Kaklamanis L, **Sotiropoulou G**, Georgoulis V, Lianidou ES. "Association of cystatin M (CST6) methylation status and clinical outcome in early breast cancer." *The 6<sup>th</sup> International Symposium on Minimal Residual Cancer*, Hamburg, Germany, Sept 19-22, 2007
62. **Sotiropoulou G**. "On the role of human kallikrein-related peptidase 6 (KLK6) in breast cancer", *24<sup>th</sup> Winter School on "Proteinases and Their Inhibitors-Recent Developments*, Tiers, Italy, Feb 28-Mar 4, 2007
63. Pampalakis G, Arampatzidou M, **Sotiropoulou G**. "Mechanisms of pharmacological modulation of KLK6 expression in breast tumor cell lines", *24<sup>th</sup> Winter School on Proteinases and Their Inhibitors–Recent Developments*, Tiers, Italy, Feb 28-Mar 4, 2007
64. **Sotiropoulou G**, Pampalakis G, Vlahou A, Prosnikli E, Zoumpourlis V. "On the role of human kallikrein 6 in breast cancer". *Gordon Research Conferences - GRC on Proteolytic Enzymes and Their Inhibitors*, Colby-Sawyer College New London, NH, USA, July 2-7, 2006
65. Pampalakis G, Prosnikli E, Zoumpourlis V, **Sotiropoulou G**. "Human kallikrein 6 suppresses the malignant phenotype of MDA-MB-231 human metastatic breast cancer cells". *Proceedings of the 97<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, Washington DC, USA, April 1-5, 2006
66. Borgoño CA, Michael IP, Komatsu N, **Sotiropoulou G**, Jayakumar A, Wu H, Clayman GL, Blaber SI, Blaber M, Mikolajczyk SD, Diamandis EP. (2006) Multiple human tissue kallikreins are regulated by lymphoepithelial Kazal-type inhibitor and digest desmoglein 1. *The 36<sup>th</sup> Annual European Society for Dermatological Research Meeting*, Paris, France, September 7-9, 2006

Abstract published in: *J Invest Dermatol* 126: 60, 359 S1, 2006

67. Shaw JLV, Grass L, Soosaipillai A, **Sotiropoulou G**, Diamandis EP. "Production of polyclonal antibodies, and development of a specific immunoassay for human kallikrein 15, a potential prostate and ovarian cancer biomarker". *Proceedings of the 97<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, Washington DC, April 1-5, 2006
68. **Sotiropoulou G**. "Human kallikrein 6: Mechanisms of epigenetic silencing in breast tumors. A role in breast cancer?" *Workshop on Functional Genomics of Proteases*, University of Bern, Bern, Switzerland, Nov 20-22, 2005
69. Pampalakis G, **Sotiropoulou G**. "Mechanisms of pharmacological modulation of human kallikrein 6 gene expression in breast tumor cell lines". *Proceedings of the 96<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, 46, #1850, Anaheim, CA, USA, April 16-20, 2005
70. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, **Sotiropoulou G**, Diamandis EP. "Involvement of human kallikreins in a proteolytic cascade pathway in the prostate". *Proceedings of the 96<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, 46, #4835, Anaheim, CA, USA, April 16-20, 2005
71. Sidiropoulos M, Pampalakis G, **Sotiropoulou G**, Diamandis EP. "Expression of human tissue kallikrein 5 in breast and prostate cancer cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine". *Proceedings of the 96<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, 6, #1842, Anaheim, CA, USA, April 16-20, 2005
72. **Sotiropoulou G**, Pampalakis G, Diamandis EP. "DNA methylation as a basis for the aberrant expression of the human kallikrein 6 gene in breast tumor cells". *Proceedings of the XVI Pezcoller Symposium*, Trento, Italy, June 10-12, 2004
73. Pampalakis G, Diamandis EP, **Sotiropoulou G**. "Cloning of novel KLK6 transcript variants". *Proceedings of the 95<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, Orlando, Florida, USA, 2004
74. Michael IP, **Sotiropoulou G**, Pampalakis G, Magklara A, Wasney GA, Diamandis EP. "Human kallikrein 5 (hK5): Autoactivation, substrate specificity, regulation by inhibitors and cleavage of extracellular matrix and basement membrane components". *Proceedings of the 95<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, Orlando, Florida, USA, 2004
75. **Sotiropoulou G**, Pampalakis G, Diamandis EP. "DNA methylation as a basis for the aberrant expression of the human kallikrein 6 gene in breast tumor cells". *International Conference on Chromatin structure and gene expression mechanisms as therapeutic targets*, Luxembourg, Jan 28-31, 2004
76. Sidiropoulos M, Pampalakis G, **Sotiropoulou G**, Diamandis EP. "CpG island hypermethylation as a basis for the differential NES1/KLK10 gene expression in breast ovarian and prostate cancers". *Proceedings of the 94<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, 44: 223, #1121, Toronto, Ontario, Canada, April 5-9, 2003
77. Pampalakis G, Diamandis EP, **Sotiropoulou G**. "CpG island methylation as a basis for the aberrant expression of the protease M/human kallikrein 6 gene in breast tumor cells". *Proceedings of the 94<sup>th</sup> Annual Meeting of the American Association for Cancer Research*, 44: 222, #1116, Toronto, Ontario, April 5-9, 2003
78. Tsetsenis T, Bayés A, Canals F, Pampalakis G, Aviles FX, **Sotiropoulou G**. "Protease M is an active protease which is aberrantly expressed in tumor cells and proteolytically release angiostatin from plasminogen". *Proceedings of the 93<sup>d</sup> Annual Meeting of the American Association for Cancer Research*, 43: 173, #866, San Francisco, CA, USA, April 6-10, 2002
79. **Sotiropoulou G**, Tsetsenis T, Rogakos V, Symillides G, Pampalakis G, Diamandis EP, Yiotakis A. "Overexpression of active recombinant human kallikrein 13 and characterization of its proteolytic



activity". *Proceedings of the 93<sup>d</sup> Annual Meeting of the American Association for Cancer Research*, 43: 563, #2793, San Francisco, CA, USA, April 6-10, 2002

80. **Sotiropoulou G**. "Emerging interest in the kallikrein gene family for understanding and diagnosing cancer". *A 2001 Millenium International Conference of Molecular and Tumor Biology "Stem Cell Differentiation, Genetic Reprogramming and Programmed Cell Death"* Nomikos Congress Center, Santorini, Greece, Sept 2-7, 2001
81. Shridhar R, Linebaugh BE, Miller FR, **Sotiropoulou G**, Sloane BF and Keppler D. "Cystatin M reduces lung metastasis of human MDA-MB-435 xenografts in SCID mice". *2<sup>nd</sup> General Meeting of the International Proteolysis Society*, Munich, Oct 31-Nov 4, 2001
82. **Sotiropoulou G**, Tsetsenis T, Bayés A, Aletras A, Vendrell J, Avilés FX. *Paul Basset Memorial Meeting on "Matrix metalloproteinases in physiological and pathological processes"* Strassbourg, France, Nov 24-25, 2000
83. Tsetsenis T, Bayés A, Avilés FX, **Sotiropoulou G**. "Expression and Characterization of Protease M". *FECTS XVIII, XVIIth Federation of European Connective Tissue Societies Meeting*, Patras, July 1-5, 2000
84. Yousef GM, Luo LY, Diamandis EP, **Sotiropoulou G**, Herbrick JA, Scherer SW, Grass L. "The zyme/protease M/neurosin gene maps close to the human kallikrein gene family and is hormonally regulated". *Proceedings of the 90<sup>th</sup> Annual Meeting of the American Association for Cancer Research* 40: 34-35, 1999
85. **Sotiropoulou G** et al. "Cloning and expression of a novel serine protease with differential expression in human and breast cancers". *An American Association of Cancer Research Meeting on Proteases and Protease Inhibitors in Cancer*, Nyborg, Denmark, June 14-18, 1998
86. **Sotiropoulou G** et al. "Cloning, expression and functional characterization of cystatin M and protease M". *Vth International Symposium on Proteinase Inhibitors and Biological Control*, Brdo, Ljubljana, Slovenia, Oct 4-8, 1997
87. **Sotiropoulou G**. "Differential Display in the discovery and functional analysis of genes involved in cancer metastasis". *International Conference on "Invasion and Metastasis"*, Athens, Greece, Oct 7-19, 1997
88. **Sotiropoulou G**, Anisowicz A, Sloane B, Stenman G, Sager R. "Cystatin M, a novel proteinase inhibitor with potential role in cancer". *A Cold Spring Harbor Laboratory Meeting on Cancer Genetics and Tumor Suppressor Genes*, Cold Spring Harbor, New York, USA, Aug 14-18, 1996
89. **Sotiropoulou G**, Anisowicz A, Sloane BF, Stenman G, Sager R. "Cystatin M, a novel proteinase inhibitor with potential role in cancer". *An American Association for Cancer Research Special Conference in Cancer Research on "Proteases and Protease Inhibitors"*, Panama City Beach, FL, USA, March 1-5, 1996
90. Sager R, Sheng S, Zhang M, **Sotiropoulou G**. "Anti-proteases as anti-carcinogens", *Workshop on Mechanisms of Carcinogenesis, Keystone Symposium*, Colorado, USA, April 1996
91. Dionyssopoulou H, **Sotiropoulou G**, Cordopatis P, Sloodstra J, Puijk W, Melen R. "Identification of epitope sequences on the extracellular domain of the beta chain of the interleukin-2 receptor by means of the PEPSCAN method". *NATO ASI Vaccine Design: The Role of Cytokine Networks*, Cape Sounio Beach, Greece, June 24-July 5, 1996
92. **Sotiropoulou G**, Anisowicz A, Ryan K, Sager R. "Isolation of a novel protease inhibitor involved in breast cancer and senescence". *1st World Congress on Advances in Oncology*, Athens, Greece, Oct 22-26, 1995
93. **Sotiropoulou G**, Anisowicz A, Sager R. "Isolation, cloning and expression of a novel protease inhibitor that is down-regulated in cancer cell lines, by means of the differential display method".

NATO ASI Regulation of Cell Growth, Differentiation and Genetics of Cancer, Porto Carras, Chalkidiki, Greece, Sept 1-12, 1995

94. **Sotiropoulou G**, Anisowicz A, Ryan K, Sager R. Isolation of a novel protease inhibitor involved in breast cancer and senescence». *Int J Oncol Suppl.* 7: 969, 1995
95. **Sotiropoulou G**, Anisowicz A, Sager R. "Novel genes involved in senescence and cancer". *Gordon Conference on the Biology of Aging*, Il Ciocco, Italy, May 7-12, 1995
96. Sager R, Sheng S, Anisowicz A, **Sotiropoulou G**, Zou Z, Swisshelm K, Hendrix M, Thor A, Ryan K, Rafidi K, Seftor E. "RNA genetics of breast cancer: Maspin as an example". *Cold Spring Harbor Symposia on Quantitative Biology, The Molecular Genetics of Cancer*, Cold Spring Harbor, New York, USA, 1994

## GREEK MEETINGS (2016-2018)

Ευάγγελος Μπισύρης, Ελένη Τσιαούση, Ελένη Ζήνγκου, Γκόλφω Κορδοπάτη, Πλάτων Μαγκριώτης, Γεώργιος Παμπαλάκης, **Γεωργία Σωτηροπούλου\*** (2019) Ανάπτυξη και αξιολόγηση ιχνηθετών ενζυμικής ενεργότητας για σερίνοπρωτεάσες-Εργαλεία μοριακής διάγνωσης και πιθανά φαρμακομόρια. 17<sup>ο</sup> Πανελλήνιο Συνέδριο Κλινικής Χημείας (17<sup>th</sup> Panhellenic Congress of Clinical Chemistry), 21-23 November 2019, Athens, Greece

Γεώργιος Παμπαλάκης\*, Ελένη Ζήνγκου, **Γεωργία Σωτηροπούλου\*** (2016) Σχεδιασμός θεραπευτικών προσεγγίσεων για το Σύνδρομο Netherton και αξιολόγηση σε ζωικά πρότυπα. 3ο Σχολείο Κλινικής Ανοσολογίας, 9-11 Δεκεμβρίου 2016, Βυτίνα [Abstract Book]

Georgios Pampalakis, Vasia-Samantha Sykioti, Methodios Ximerakis, Ioanna Stefanakou-Kalakou, Ronald Melki, Kostas Vekrellis, **Georgia Sotiropoulou\*** (2016) KLK6 proteolysis is implicated in regulation of the turnover and uptake of extracellular alpha-synuclein species. Session: "Molecular and Cellular Basis of Human Disease". 67<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας (EEBMB). 25-27 Νοεμβρίου 2016 στα Ιωάννινα [Oral Presentation, ACT1100]

Eleni Charla, Eleni Zingkou, Georgios Pampalakis, **Georgia Sotiropoulou\*** (2016) A novel double knockout (*Spink5<sup>-/-</sup>Klk6<sup>-/-</sup>*) mouse model reveals a role of the KLK6 protease in skin inflammation. Session: "Molecular and Cellular Basis of Human Disease". 67<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας (EEBMB). 25-27 Νοεμβρίου 2016 στα Ιωάννινα [Poster, ACT1101]

Nicola Khoury, Georgios Pampalakis, Eleni Zingkou, Vassilis Zoumpourlis, **Georgia Sotiropoulou\*** (2016) Development and progression of non-melanoma skin cancer is inhibited in *Klk6<sup>-/-</sup>* mice. Session: "Cancer". 67<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας (EEBMB). 25-27 Νοεμβρίου 2016 στα Ιωάννινα [Poster, ACT1102]

Eleni Zingkou, Georgios Pampalakis, Eleni Charla, **Georgia Sotiropoulou\*** (2016) Targeting KLK5 alone rescues neonatal lethality associated with Netherton Syndrome but cannot sustain a normal epidermal barrier function. Session: "Molecular and Cellular Basis of Human Disease". 67<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας (EEBMB). 25-27 Νοεμβρίου 2016 στα Ιωάννινα [Poster, ACT1221]

Stefanakou-Kalakou I, Pampalakis G, Ximerakis M, Sykioti VS, Vekrellis K, **Sotiropoulou G**. "Insights into a proteolytic cascade engaged in extracellular  $\alpha$ -synuclein processing." 65<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας, Θεσσαλονίκη, 28-30 Νοεμβρίου, 2014

Pampalakis G, Zingkou E, Spella M, Stathopoulos G, López-Otín C, **Sotiropoulou G**. "Elimination of Kik5 inhibits skin carcinogenesis by inhibiting  $\beta$ -catenin signaling. " 65<sup>ο</sup> Πανελλήνιο Συνέδριο της Ελληνικής Εταιρείας Βιοχημείας και Μοριακής Βιολογίας, Θεσσαλονίκη, 28-30 Νοεμβρίου, 2014

Kioulafa M, Kaklamanis L, **Sotiropoulou G**, Georgoulas V, Lianidou ES. "Association of cystatin M (CST6) methylation status and clinical outcome in early breast cancer." 59<sup>th</sup> Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, 2007

## TEXTBOOKS - GREEK EDITIONS

### 1. "Pharmaceutical Biotechnology. Fundamentals and Applications"\* (3<sup>rd</sup> Edition)

Daan JA Crommelin, Robert D Sindelar, Bernd Meibohm (Informa, 2008)

*Τίτλος Ελληνικής Έκδοσης:* "Φαρμακευτική Βιοτεχνολογία. Βασικές Αρχές και Πρακτικές Εφαρμογές" (Πανεπιστημιακές Εκδόσεις Παρισιάνου, 2011)

*Επιμέλεια Ελληνικής Έκδοσης:* A Tsiftoglou, G Sotiropoulou

## EDITORIAL GROUP MEMBER

### 2. "Principles of Molecular Biology: Genes to Proteins"

Burton E. Tropp (Jones & Bartlett Publishers, 2012)

*Greek Edition:* "Βασικές Αρχές Μοριακής Βιολογίας"

Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2015

### 3. "The Cell: A Molecular Approach" (5<sup>th</sup> Edition)

Cooper GM, Hausman RE (Sinauer, 2009)

*Greek Edition:* "Το Κύτταρο: Μια Μοριακή Προσέγγιση"

Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2011

### 4. "Molecular Biology of the Gene" (6<sup>th</sup> edition)

James D Watson, Tania A Baker, Stephen P Bell, Alexander Gann, Michael Levine, Richard Losick (CSHLP, Pearson, Benjamin Cummings, Prentice Hall, 2008)

*Greek Edition:* "Μοριακή Βιολογία του Γονιδίου"

Utopia Publishing, 2010

### 5. "Recombinant DNA. Genes and Genomes – A Short Course"

James Watson, Amy Caudy, Richard Myers, Jan Witkowski

WH Freeman and Company, Cold Spring Harbour Laboratory Press (2007)

*Greek Edition:*

"Ανασυνδυασμένο DNA. Γονίδια και Γονιδιώματα - Μια Συνοπτική Παρουσίαση"

Ακαδημαϊκές Εκδόσεις Ι. Μπάσδρα και ΣΙΑ ΟΕ, 2007

## HANDOUTS FOR LABORATORY TRAINING

1. G Sotiropoulou, I Zarkadis (Patras, 2007) Laboratory Exercises for the Undergraduate Course "Pharmaceutical Biotechnology"
2. G Sotiropoulou, G Pampalakis (Patras, 2010; 2006-2009 earlier versions) Laboratory Exercises for the Undergraduate Course "Molecular Biology-Genetics"

## DISTANCE LEARNING

Production of Alternative Teaching Material in HYPERTEXT format (EAP/GOU: KFE53)

*Topics:* Cell division and cancer: Regulation of cell cycle, apoptosis, oncogenes, and tumor suppressor genes. Techniques and methodologies for analysis of mutations.